MOLECULAR APPROACHES FOR CONTROLLING RNA STABILITY by Borchardt, Erin
 
MOLECULAR APPROACHES FOR CONTROLLING RNA STABILITY 
 
Erin Katherine Borchardt 
 
A dissertation submitted to the faculty at the University of North Carolina at Chapel Hill 
in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the 
Curriculum in Genetics and Molecular Biology in the School of Medicine. 
 
Chapel Hill 
2016 
 
Approved by: 
 
Aravind Asokan 
 
William F. Marzluff 
 
Alain Laederach 
 
Brian Kuhlman 
 
Dale A. Ramsden
ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 
Erin Katherine Borchardt 
ALL RIGHTS RESERVED 
 
iii 
 
ABSTRACT 
Erin Katherine Borchardt: Molecular Approaches for Controlling RNA Stability 
(Under the direction of Aravind Asokan)  
Nature utilizes a number of methods for regulating gene expression via 
modulation of RNA stability. Factors involved in these processes include microRNAs, 
nucleotide modifications, structural elements, and ribonucleases, among others. In this 
dissertation, we aim to develop novel approaches for controlling gene expression 
through the manipulation of RNA stability. Prokaryotic CRISPR systems have provided 
a wealth of new tools for a range of molecular biology applications. A large proportion of 
these CRISPR-based technologies rely on CRISPR-associated nucleases to cleave 
either target DNA or RNA. The CRISPR endoribonuclease, Csy4 (Cas6f), is one such 
CRISPR protein, which specifically interacts with, and cleaves a target RNA hairpin. 
Here, we explore the use of Csy4 for destabilizing and stabilizing RNA transcripts in 
mammalian cells. We find that Csy4 is capable of knocking down gene expression when 
targeting the 5’UTR or coding sequence of a reporter mRNA. Additionally, Csy4 can 
rescue destabilized transcripts when targeted to the 3’UTR, and can promote their 
translation. We utilize the ability of Csy4 to stabilize target hairpin-containing cleavage 
products to induce RNA circularization of an engineered RNA splicing reporter. Further, 
we demonstrate the use of recombinant Adeno-Associated Virus (rAAV)-delivered 
circular RNA (circRNA) expression cassettes as platforms for gene expression in vivo. 
We find that these circRNAs can be translated to produce protein products in mice, and 
iv 
we observe expression differences between heart and highly proliferative liver tissue. 
The new approaches presented here provide starting points for the development of a 
number of new technologies including genetic ‘safety switches’ and genetic cassettes 
capable of therapeutic gene expression at lower rAAV vector dosages.  
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CHAPTER 1: INTRODUCTION 
1.1 CRISPR Systems 
Prokaryotic organisms regularly encounter foreign genetic elements which pose 
a threat to their survival. As such, ~45% of bacteria and ~83% of archaea utilize the 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system as a 
mechanism of defense against these invading nucleic acids (Grissa et al., 2007). 
CRISPR systems neutralize foreign nucleic acid using a combination of proteins 
and RNA elements encoded within CRISPR loci. These loci are typically characterized 
by the presence of a repeat-spacer-array, a leader sequence, and a series of CRISPR-
associated (Cas) protein encoding genes. Within the repeat-spacer array, short 
repeating motifs flank unique sequence elements (spacers) which share sequence 
homology with previously encountered foreign nucleic acid (Barrangou et al., 2007a; 
Bolotin et al., 2005; Mojica et al., 2005; Pourcel et al., 2005). The leader sequence, 
which exhibits promoter activity, is involved in expressing the repeat-spacer array and in 
acquisition of new spacer sequences (Pul et al., 2010; Wei et al., 2015). The protein 
products of Cas genes are responsible for carrying out essential steps in the CRISPR 
pathway, ultimately leading to target neutralization.  CRISPR-based immunity is carried 
out in three general stages: acquisition (adaptation), expression and maturation, and 
interference (Figure 1). However, CRISPR systems vary in their exact mechanisms to 
carry out each of these stages, owing to a diverse range of Cas proteins. As such, 
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CRISPR systems have been divided into classes, types, and subtypes, discussed 
below.  
 
CRISPR Classification: 
CRISPR systems are functionally categorized into two classes based on their 
complement of Cas proteins (Makarova et al., 2015). CRISPR classes are divided into 
five types denoted by roman numerals, which are further separated into 16 subtypes 
denoted by alphabetical letters (Makarova et al., 2015). All functional CRISPR systems 
require the presence of both Cas1 and Cas2, which are essential for the adaptation 
stage of CRISPR immunity.  Accessory Cas proteins provide the basis for classification 
and specify the mechanistic differences of immunity between each CRISPR subtype. 
Class 1 CRISPR systems are characterized by a multi-subunit protein complex of Cas 
proteins which is utilized to carry out target neutralization. Conversely, Class 2 CRISPR 
systems utilize a single Cas protein to mediate CRISPR immunity.  
 
CRISPR Adaptation: 
Initial studies exploring CRISPR immunity recognized that spacer sequences 
were identical to sequences present in phage and plasmids (Bolotin et al., 2005; Mojica 
et al., 2005; Pourcel et al., 2005). In addition, studies demonstrated that phage-resistant 
Streptococcus thermophilus could be generated by challenging the bacteria with 
bacteriophage of interest and isolating survivors. Evaluation of the CRISPR locus in 
these strains revealed the addition of one or more spacer sequences corresponding to 
the specific bacteriophage the repeat-spacer array (Barrangou et al., 2007b). Further, if 
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these spacer sequences were subsequently deleted from the bacteria, their acquired 
resistance was lost (Barrangou et al., 2007b). Together, these data determined a 
relationship between the spacer sequence and CRISPR-mediated immunity. In 
particular, this study established the fundamental adaptability of the CRISPR system, 
demonstrating that new, immunizing spacers can be acquired upon exposure to a 
pathogen.  
The acquisition (or adaptation) phase of CRISPR immunity requires Cas1 and 
Cas2 to incorporate a small segment of foreign nucleic acid sequence as a new spacer 
in the repeat-spacer array (Nunez et al., 2015; Yosef et al., 2012) (Figure 1). Integration 
of a new spacer into the repeat-spacer array always occurs at the leader proximal end 
of the array (Barrangou et al., 2007b). The original sequence of the spacer, found in the 
foreign nucleic acid, is known as the protospacer. A protospacer adjacent motif (PAM) 
immediately flanking the protospacer is utilized by the adaptation machinery for 
recognizing new potential spacer sequences (Heler et al., 2015).  
Interestingly, CRISPR systems also appear to be primed for acquisition of new 
spacers against previously encountered targets. Such primed acquisition occurs when a 
particular target shares partial homology with a spacer that is already present in the 
repeat-spacer array (Datsenko et al., 2012; Swarts et al., 2012). This may represent a 
mechanism for combatting bacteriophage that escape from CRISPR targeting by 
mutating their protospacers (Datsenko et al., 2012).  
 
CRISPR Expression and Maturation: 
           In the expression and maturation stage of CRISPR immunity, the repeat-spacer 
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array is transcribed into a single, long precursor transcript (pre-crRNA) (Figure 1). 
Transcription of the pre-crRNA is driven by a promoter in the leader sequence (Pul et 
al., 2010). The pre-crRNA is subsequently processed by Cas proteins into small 
CRISPR RNAs (crRNAs) such that each crRNA contains a single spacer and a partial 
repeat handle. The pre-crRNA processing step of the CRISPR pathway varies between 
CRISPR types and subtypes. For example, in the Class 1 Type-IF CRISPR system of 
Pseudomonas aeruginosa, the task of crRNA biogenesis falls to Csy4 (Cas6f) (Cady 
and O'Toole, 2011; Haurwitz et al., 2010). However, in Class 2 type II CRISPR systems, 
the combined efforts of Cas9, cellular Ribonuclease III, and an additional small RNA 
(trans-activating CRISPR RNA, or tracrRNA) are responsible for pre-crRNA processing 
(Karvelis et al., 2013).  
 
CRISPR Interference: 
During the interference phase, Cas nucleases are guided to their targets by 
crRNAs in a sequence specific manner (Figure 1). An important checkpoint in 
distinguishing target from self occurs in most CRISPR systems during the interference 
stage. In this step, the interference complex interrogates the sequence adjacent to the 
protospacer for a PAM. If the PAM is present, the Cas nuclease is licensed to cleave 
the target, rendering the invading nucleic acid inactive (Sternberg et al., 2014; 
Szczelkun et al., 2014). Verification of the PAM sequence prevents targeting of the 
genomic CRISPR locus, which contains crRNA binding sites but lacks a PAM. 
As in the expression and maturation phase, the mechanistic details of CRISPR 
interference vary by CRISPR class and type. For example, PAM sequences vary 
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between CRISPR subtypes, both in sequence and location relative to the protospacer 
(5' or 3') (Shah et al., 2013). Further, in Class 1 systems, the interference complex is 
formed by crRNA interaction with a multi-subunit Cas protein complex. Target cleavage 
is carried out by Cas3 in Class 1 Type I systems while Cas10 carries out this task in 
Class 1 Type III systems (Brouns et al., 2008; Hatoum-Aslan et al., 2014; Samai et al., 
2015; Sinkunas et al., 2011; Westra et al., 2012). In comparison, Class 2 systems utilize 
a single Cas protein bound to crRNA to form the effector complex (Makarova et al., 
2015). In Class 2 Type II systems, this task falls to Cas9. (Barrangou et al., 2007b; 
Garneau et al., 2010b; Jinek et al., 2012; Sapranauskas et al., 2011).  
 
1.2 Pre-crRNA Processing by Csy4 
Csy4 (Cas6f) is a CRISPR endoribonuclease member of Class 1 Type IF 
CRISPR systems. Functioning in the expression stage of CRISPR immunity, Csy4 
cleaves the pre-crRNA at regular intervals to generate small crRNAs (Cady and 
O'Toole, 2011; Haurwitz et al., 2010). In the P. aeruginosa Type I-F CRISPR system, 
each repeat in the repeat-spacer array consists of 28 nucleotides. Sixteen of these 
nucleotides form a short hairpin which serves as the substrate for Csy4 binding and 
cleavage. Csy4-mediated cleavage occurs at the 3' base of each hairpin stem, 
generating a terminal 3'-phosphate (Wiedenheft et al., 2011) (Figure 2C). Each resulting 
crRNA contains a unique 32-nucleotide spacer flanked by portions of repeat-derived 
sequences on either side (Wiedenheft et al., 2011). Csy4 remains tightly associated 
with the processed crRNA product and complexes with additional Cas proteins for the 
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interference stage of the CRISPR pathway (Sternberg et al., 2012; Wiedenheft et al., 
2011).  
Csy4 and the target hairpin form a high affinity interaction (Kd ≈ 50 pM) which is 
dependent on both sequence- and structure-specific contacts (Haurwitz et al., 2010; 
Sternberg et al., 2012). A positively charged, arginine-rich helix docks into the major 
groove of the hairpin stem (Haurwitz et al., 2010) (Figure 2A, B). Within the arginine-rich 
helix, Arg114, Arg115, Arg118, Arg119 and His120 make contact with phosphate 
groups in the RNA hairpin (Haurwitz et al., 2010) (Figure 2A). When a subset of these 
arginine residues are mutated, the capacity of Csy4 to bind the substrate hairpin is 
greatly reduced (Sternberg et al., 2012). Nucleotide-specific contacts are specified by 
hydrogen bonding between Arg102 and G20, Gln104 and A19, and Arg115 and G11 
(Haurwitz et al., 2010) (Figure 2A). Lastly, Phe155 interacts with, and positions G20 in 
the enzyme active site via base-stacking interactions (Haurwitz et al., 2010; Sternberg 
et al., 2012) (Figure 2A). 
The Csy4 active site relies on two critical amino acids for catalysis, Ser148 and 
His29 (Figure 2A). Mutation of either of these residues to cysteine and alanine 
respectively renders Csy4 inactive (Haurwitz et al., 2010). Subsequent studies 
determined that Ser148 is required for positioning a 2' hydroxyl group within the active 
site while His29 acts as a general base for the cleavage reaction (Sternberg et al., 
2012). 
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1.3 CRISPR Components as Tools 
CRISPR systems have provided the basis for a breadth of new technologies 
ranging from bacterial genotyping to genome engineering (Selle and Barrangou, 2015; 
Wright et al., 2016). Much of the original focus on CRISPR was aimed at developing 
tools for application in the dairy industry, which relies on valuable bacterial starter 
cultures. Initial studies sought new techniques for vaccination of bacteria against 
bacteriophages and drove many seminal CRISPR findings (Barrangou et al., 2007b; 
Deveau et al., 2008; Horvath et al., 2008). As such, a number of CRISPR tools support 
the study and maintenance of bacteria commonly used in the food industry. For 
example, the consistent integration of new spacers at the leader proximal side of the 
repeat-spacer array records a sequential history of exposure to foreign nucleic acid 
(Barrangou et al., 2007b). This trait has been exploited for the genotyping of various 
bacteria (Grissa et al., 2009; Vergnaud et al., 2007).  
Perhaps the most widely appreciated CRISPR-based tool is Cas9, an RNA 
guided nuclease present in all Class 2 type-II CRISPR systems (Makarova et al., 2015). 
During the interference phase, Cas9 is guided to foreign DNA targets through the 
specificity of a crRNA. Cas9’s interaction with the crRNA is bridged by an additional 
small RNA called the trans-activating crRNA (tracrRNA) (Deltcheva et al., 2011). The 
Cas9-crRNA-tracrRNA complex is guided to foreign DNA through the sequence 
specified by the crRNA, where Cas9 mediates a double strand break. It was discovered 
that the tracrRNA and crRNA could be linked together to form a single RNA termed a 
guide-RNA (gRNA) (Jinek et al., 2012). This specificity of the gRNA can be easily 
programmed by replacing the crRNA region with 20 nucleotides targeting nearly any 
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region of interest. Consequently, Cas9 can be guided to cleave any sequence, provided 
the appropriate PAM is present.  
Cas9 is an attractive tool for genome engineering, and a myriad of other 
applications, due to the ease of which it can be programmed. Initial applications of Cas9 
focused on genome editing but have since expanded to include functions such as RNA-
guided RNA imaging and transcriptional control (Gilbert et al., 2013; Mali et al., 2013a; 
Nelles et al., 2016). Furthermore, Cas9 seems to function in nearly every organism 
tested, ranging from bacteria to human cell lines (Cong et al., 2013; DiCarlo et al., 2013; 
Friedland et al., 2013; Gratz et al., 2013; Hwang et al., 2013; Jiang et al., 2013; Jinek et 
al., 2013; Li et al., 2013; Mali et al., 2013b; Nekrasov et al., 2013; Wang et al., 2013).  
However, the use of Cas9 is limited in a few ways. First, target selection is 
restricted to sequences containing the PAM sequence of the particular Cas9 ortholog 
being used for cleavage. For Streptococcus pyogenes Cas9, the Cas9 ortholog utilized 
in initial Cas9 genome editing studies, the PAM requirement restricts gRNA design to 
sequences with a 3' NGG motif (Mojica et al., 2009). In addition, gRNA expression is 
restricted to RNA polymerase III promoters in vivo. The U6 promoter, which requires 
guanine as the first nucleotide in the gRNA tends to be preferred, adding an additional 
sequence constraint to gRNA selection. Limiting expression at the promoter level also 
hinders the use of tissue specific and conditional expression regulation. However, a 
solution to these promoter restrictions was found in another Cas protein, Csy4. Csy4 
hairpins were incorporated flanking a gRNA such that co-expression with Csy4 will 
result in cleavage and separation from other RNA elements in a transcript (Nissim et al., 
2014; Tsai et al., 2014). This allows expression from polymerase II promoters without 
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interference from sequences that may affect gRNA, function, stability, or localization. 
Further, multiple gRNA can be expressed from a single promoter if Csy4 hairpins are 
placed between each gRNA, allowing multiplexed Cas9 applications (Nissim et al., 
2014; Tsai et al., 2014).  
Csy4 has also formed the basis of a number of other tools and techniques. 
Inactivation of Csy4 catalytic activity through a H29A mutation has allowed for Csy4-
mediated purification of hairpin-tagged RNA transcripts (Lee et al., 2013; Salvail-
Lacoste et al., 2013). The purified transcripts can subsequently be analyzed for 
identification of proteins associated with a transcript of interest (Lee et al., 2013). 
Additionally, Csy4 has been adapted for gene regulation and processing RNA 
transcripts encoding multiple genes in Escherichia coli, Bacillus subtilis, and 
Saccharomyces cerevisiae (Qi et al., 2012). Csy4 was also utilized in regulating 
translation of prokaryotic gene expression (Du et al., 2016a). In this context, Csy4 
hairpins separated a ribosome binding site (RBS) and open reading frame (ORF) from 
an upstream cis-repressive RNA. The cis-repressive RNA functions by hybridizing with, 
and masking the RBS, preventing ribosomal loading and translation. Upon co-
expression with Csy4, the cis-repressive RNA is cleaved away, exposing the RBS, and 
allowing translation (Du et al., 2016a). Csy4 has also been used to regulate viral 
infection (Guo et al., 2015). For this application, Csy4 was fused to HIV Viral Protein R 
(VPR) in an effort to guide Csy4 to the HIV particle. The Csy4 hairpin was incorporated 
into the 3’ end of the HIV genome before the LTR, as a target for Csy4 cleavage. 
Expression of the Csy4-VPR fusion in HIV infected cells resulted in undetectable HIV 
levels, demonstrating Csy4-mediated viral inhibition (Guo et al., 2015).    
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Two new applications of Csy4 are delineated in this dissertation. Chapter 2 
details the development of Csy4 as a tool for regulating the stability and translation of 
transgene-derived RNA. Chapter 3 describes the utilization of Csy4 for inducing 
engineered circular RNA formation.  
 
1.4 Sequence Elements Involved in RNA Stability  
RNA stability is tightly controlled in cells using a wide range of methods. Of note, 
are 3' end stabilizing sequences, which protect the 3' ends of RNAs from exonucleolytic 
degradation. The majority of mammalian cellular mRNAs are terminated at the 3' end 
with a poly(A) tail. The poly(A) tail ensures mRNA stability through recruitment of the 
poly(A) binding protein Pab1p (Coller et al., 1998). Interestingly, not all eukaryotic 
mRNAs possess a poly(A) tail, and these RNAs must ensure stability by distinct 
mechanisms. For example, replication-dependent histone mRNAs possess a 3' terminal 
stem loop structure in place of a poly(A) tail. The persistence of these mRNAs is 
influenced by a set of proteins interacting with the stem loop and stem loop binding 
protein (SLBP) to promote either maturation or degradation in a cell cycle dependent 
manner (Marzluff et al., 2008).  
In addition, triple helical elements have demonstrated the capacity to mediate 3' 
RNA end stabilization. Triple helix elements have been identified thus far in the 3' ends 
of non-coding and viral RNAs. The MALAT1 (metastasis-associated lung 
adenocarcinoma transcript 1) RNA, also known as NEAT2, is a long noncoding RNA 
which accumulates to high abundance in mouse and human cells (Hutchinson et al., 
2007; Zhang et al., 2012). The MALAT1 RNA gains stability via an RNase P mediated 
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cleavage event to remove a tRNA-like structure called the mascRNA (MALAT1-
associated small cytoplasmic RNA). The resulting 3' end of the MALAT1 transcript folds 
into a triple helical structure which is resistant to exonucleolytic degradation (Brown et 
al., 2012; Wilusz et al., 2012). MALAT1 triple helix-mediated stability can be conferred 
to an RNA of interest by simply placing the 3' end of the MALAT1 transcript at the 3' end 
of the RNA. Surprisingly, when placed downstream of an ORF lacking a poly-
adenylation signal, the MALAT1 3' end is also capable of supporting protein translation 
(Wilusz et al., 2012).  
Viruses, such as Kaposi’s sarcoma-associated herpesvirus (KSHV) also make 
use of triple helix elements. In the KSHV polyadenylated nuclear (PAN) RNA, a triple 
helix is formed within an expression and nuclear retention element (ENE). The ENE 
contains a U-rich loop which sequesters and protects the PAN RNA poly(A) tail (Conrad 
et al., 2006; Mitton-Fry et al., 2010). The resulting triple helical structure stabilizes the 
PAN RNA and protects it from exonucleolytic degradation (Conrad et al., 2006). 
Structure-based bioinformatics analysis has since identified similar ENEs in a range of 
viral genomes (Tycowski et al., 2012). The occurrence of ENEs in a diverse set of viral 
genomes highlights the utility and value of this stabilizing structure. 
 
1.5 Circular RNAs 
Circular RNAs (circRNAs) are highly stable, covalently closed RNAs. Typically, 
circRNAs are generated through backsplicing, a process in which a downstream 
splicing donor joins with an upstream splicing acceptor (Jeck et al., 2013). However, an 
alternate mechanism which proceeds through a lariat intermediate has been proposed 
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(Zaphiropoulos, 1996). Another class of circRNAs, tRNA intronic circular RNAs 
(tricRNAs), are generated using tRNA maturation machinery (Lu et al., 2015).  
Components of the canonical splicing machinery and splicing signals have been 
identified as factors involved in circRNA formation (Starke et al., 2015). However, 
circRNA biogenesis can be facilitated by a number of both trans- and cis-acting factors. 
For instance, circularization of a subset of circRNAs is regulated by the alternative 
splicing factor, Quaking, during the human epithelial to mesenchymal transition (Conn et 
al., 2015). Similarly, the muscleblind (MBL) protein is involved in circularization of the 
MBL circRNA. This observation might suggest an autoregulatory role for MBL in which 
excess of MBL favors the circularization of its flanked exon. This would in turn reduce 
the amount of linear, MBL encoding transcript (Ashwal-Fluss et al., 2014). Furthermore, 
circMBL itself contains MBL binding sites and is capable of binding MBL protein, 
contributing to the potential autoregulatory feedback loop (Ashwal-Fluss et al., 2014). 
Cis-acting factors are also involved in circRNA biogenesis. Of recent interest are 
inverted repeat sequences (e.g. Alu repeats in humans) which have been found flanking 
exons known to circularize. These inverted repeat sequences are essential for the 
circularization of the intervening exon(s) (Ashwal-Fluss et al., 2014; Ivanov et al., 2015; 
Jeck et al., 2013; Kramer et al., 2015; Liang and Wilusz, 2014; Zhang et al., 2014). 
Circularization mediated by inverted repeats is thought to occur through a mechanism in 
which base pairing brings splice sites in close proximity to facilitate backsplicing. 
Consistent with this hypothesis, ADAR enzymes, which deaminate adenosine to inosine 
and unwind double-stranded regions of RNAs, inhibit circRNA formation (Ivanov et al., 
2015). 
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Regardless of their mechanism of biogenesis, circRNA’s are markedly more 
stable than their linear counterparts.  The lack of exposed 3' and 5' ends likely renders 
circRNAs resistant to a number of cellular exonucleases. Consequently, this inherent 
stability leads to sustained persistence of circRNAs (Jeck et al., 2013; Lasda and 
Parker, 2014; Liang and Wilusz, 2014). This is exemplified by the median half-life of 
circRNAs, which is at least 2.5X longer than that of their linear counterparts (Enuka et 
al., 2015).  
 Deep sequencing studies have revealed differences in the abundance of various 
circRNAs, which are dictated by tissue, cell type, and developmental stage (Memczak et 
al., 2013). CircRNAs are known to be highly abundant in the mammalian brain 
compared to other tissues. In particular, they appear to be enriched at the synapses and 
synthesized during neuronal differentiation and development (Rybak-Wolf et al., 2015; 
You et al., 2015). Synaptic localization of certain circRNAs also suggests that they may 
be specifically targeted to different sites in the cell, as their linear counterparts are 
localized in the cytoplasm (Rybak-Wolf et al., 2015). This suggests possible specific 
roles for circRNAs at the synapse. Though they are often most highly expressed in the 
brain, circRNAs are also expressed in non-neuronal tissues. For example, the 
ZKSCAN1 circRNA is also detected in the liver while the HIPK3 circRNA is detected in 
the kidney, heart, lung, thyroid, and uterus. (Liang and Wilusz, 2014).   
Despite their abundance, the functions for most circRNAs remains to be 
determined (Ebbesen et al., 2015). The roles of a small number of circRNAs have been 
proposed, but it is likely that there are a wide variety of possible functions. One 
hypothesis posits that the biogenesis of circRNAs may serve as a method of alternative 
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splicing regulation. This regulation would be carried out by affecting exon skipping, due 
to the mutually exclusive relationship between circular and linear splicing of an exon 
(Ashwal-Fluss et al., 2014). Alternatively, some circRNAs such as circHIPK3, ciRS-7 
(Cdr1as) and the Sry circRNA act as microRNA (miRNA) sponges (Hansen et al., 2013; 
Memczak et al., 2013; Zheng et al., 2016). However, most circRNAs are not enriched 
for miRNA binding sites and this is unlikely to be a general function of circRNAs (Guo et 
al., 2014). As described above, circMbl has been proposed as a sponge for MBL 
protein, and some circRNAs containing introns (EIciRNAs) have been implicated in 
transcription regulation (Ashwal-Fluss et al., 2014; Li et al., 2015). Additionally, 
circFoxo3 appears to bind the cell cycle regulators CDK2 (cyclin dependent kinase 2) 
and p21 to repress cell cycle progression (Du et al., 2016b). CircRNAs have also been 
proposed as templates for retrotranscription and reinsertion into the genome to 
generate pseudogenes (Dong et al., 2016). 
Although most circRNAs arise from protein-coding exons, endogenously 
encoded circRNAs are not associated with ribosomes in the cytosol and no examples of 
translated endogenous circRNAs have been described (Capel et al., 1993; Guo et al., 
2014; Jeck et al., 2013). However, studies suggest circRNAs can be engineered to 
express a protein of interest if an internal ribosome entry site (IRES) is included to drive 
translation (Chen and Sarnow, 1995; Wang and Wang, 2015). The inherent stability of 
circRNAs and variety of potential natural and engineered functions for circRNAs make 
these molecules attractive tools expression of therapeutic genes in vivo.  
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1.6 Adeno-Associated Virus-Mediated Gene Delivery and RNA Therapeutics 
Adeno-Associated Virus (AAV) is a helper-dependent parvovirus with a 4.7 kb 
single stranded DNA genome. AAV utilizes three promoters to express a series of 
proteins though overlapping reading frames in Rep and Cap genes. The genome is 
flanked on either end by inverted terminal repeat (ITR) sequences which are essential 
for genome packaging into the viral capsid (Figure 3A). The ITRs are the only cis-
elements required for genome packaging. As such, AAV can be converted into a 
recombinant vector for gene therapy by replacing the intervening sequence with an 
expression cassette of interest (Figure 3B).   
As a gene therapy vector, recombinant AAV (rAAV) is particularly valuable due to 
long-term transgene expression, lack of pathogenicity, and inability to replicate 
independently (Samulski and Muzyczka, 2014). Further, the tropism of a number of 
serotypes is well defined and can be engineered through capsid manipulations (Asokan 
et al., 2012; Pulicherla et al., 2011a; Shen et al., 2013b). rAAV can be generated and 
purified through a triple plasmid transfection protocol in HEK293 cells, and can package 
any ITR-flanked cassette less than 4.7 kb in size (Xiao et al., 1998). These features 
make rAAV an ideal vector for delivery of therapeutic genes in mice and potentially 
higher order mammals. In particular, the well-studied tropism of various AAV serotypes 
allows for direct targeting of specific tissues and cell types. This prevents exposing the 
entire organism to the therapeutic in situations where it might not be necessary or may 
be detrimental.  
rAAV-based therapeutics are poised for the treatment of a range of genetic 
diseases. Current studies are exploring the potential of rAAV-mediated delivery of 
16 
treatments for factor IX deficiency (hemophilia B), lysosomal storage diseases, and 
alpha-1-antitrypsin (AAT) deficiency, among others (Brimble et al., 2016; Hinderer et al., 
2015; Samulski and Muzyczka, 2014; Wozniak et al., 2015). rAAV-mediated delivery of 
Cas9 and gRNA has shown promise for treatment of Duchenne’s muscular dystrophy 
(Long et al., 2016; Nelson et al., 2016; Tabebordbar et al., 2016). Additionally, rAAV-
based treatment developed for Leber’s congenital amaurosis, a form of blindness, has 
been successful (Cideciyan et al., 2008; Maguire et al., 2008). An rAAV-delivered 
treatment for lipoprotein lipase deficiency (Glybera) has been approved in Europe, and 
represents the first approved rAAV therapeutic in the West (Bryant et al., 2013; Gaudet 
et al., 2010).  
rAAV vectors have been successfully used for the expression of RNA 
therapeutics such as short hairpin RNAs (shRNA) and miRNAs in a number of animal 
models (Borel et al., 2014). While well-tolerated in the majority of cases, overexpression 
of AAV-shRNA vectors have been shown to cause hepatotoxicity or neurotoxicity in 
some examples (Grimm et al., 2006; van Gestel et al., 2014). This is likely due to their 
potential to saturate the miRNA pathway and consequently alter the normal cellular 
miRNA composition (Grimm et al., 2006; Valdmanis et al., 2016; van Gestel et al., 
2014). Further, though many clinical trials utilizing rAAV for expression of therapeutic 
proteins have proved encouraging, vector dose-related toxicity remains a concern 
(Nathwani et al., 2014). CircRNA expression cassettes may help to alleviate dose-
toxicity issues through stable expression of therapeutic genes at potentially lower 
clinical doses. Chapter 4 describes methods for AAV-mediated delivery of circRNA 
cassettes.   
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Figure 1: General schematic of CRISPR mediated immunity. Upon encountering 
foreign nucleic acid, such as from a phage genome, Cas1 and Cas2 mediate 
incorporation of a new spacer into the repeat-spacer array (acquisition). The repeat-
spacer array is expressed as a pre-crRNA which is processed into mature crRNAs by 
Cas proteins (expression and maturation). A Cas nuclease is guided to target nucleic 
acid by crRNA and mediates nucleolytic cleavage (interference).    
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Figure 2: Characteristics the Csy4-hairpin interaction. (A) PyMOL rendering of Csy4 
bound to the hairpin sequence. Catalytic residues Ser148 and His29 are displayed as 
sticks in orange. Residues making structure- and sequence-specific contacts are shown 
as sticks in blue. Hairpin ribonucleotides that are recognized in a sequence-specific 
manner are displayed in yellow. Sequence-specific interactions are enlarged to the right 
in boxes. (B) Charge-smoothed surface representation model of Csy4 interacting with 
the hairpin sequence. Renderings of Csy4 in A and B are based off of PDB coordinates 
2XLK (Haurwitz et al., 2010). (C) Substrate (left) and products (right) of Csy4-mediated 
cleavage.  
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Figure 3: Genomic maps of AAV and recombinant AAV. (A) In the AAV genome, 
inverted terminal repeats (ITRs) flank Rep and Cap genes, which are expressed from 
three promoters and terminated with a poly(A) signal. (B) Recombinant AAV genomes 
can be generated by replacing the intervening sequence between the ITRs with an 
expression cassette of interest.   
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CHAPTER 2: CONTROLLING MRNA STABILITY AND TRANSLATION WITH THE 
CRISPR ENDORIBONUCLEASE CYS41 
2.1 Overview 
The bacterial CRISPR endoribonuclease, Csy4 has recently been described as a 
potential RNA processing tool. Csy4 recognizes substrate RNA through a specific 28 
nucleotide hairpin sequence and cleaves at the 3' end of the stem. To further explore 
applicability in mammalian cells, we introduced this hairpin at various locations in 
mRNAs derived from reporter transgenes and systematically evaluated the effects of 
Csy4-mediated processing on transgene expression. Placing the hairpin in the 5' 
untranslated region (UTR) or immediately after the start codon resulted in efficient 
degradation of target mRNA by Csy4 and knockdown of transgene expression by 20 to 
40-fold. When the hairpin was incorporated in the 3' UTR prior to the poly(A) signal, the 
mRNA was cleaved, but only a modest decrease in transgene expression (~2.5 fold) 
was observed. In the absence of a poly(A) tail, Csy4 rescued the target mRNA 
substrate from degradation, resulting in protein expression, which suggests that the 
cleaved mRNA was successfully translated. In contrast, neither catalytically-inactive 
(H29A) nor binding-deficient (R115A/R119A) Csy4 mutants were able to exert any of 
the above-described effects. Generation of a similar 3' end by RNase P-mediated 
cleavage was unable to rescue transgene expression independent of Csy4. These 
                                                          
1This chapter previously appeared as an article in the journal RNA. The original citation 
is as follows: Borchardt, E.K., Vandoros, L.A., Huang, M., Lackey, P.E., Marzluff, W.F. 
and Asokan, A. 2015. Controlling mRNA stability and translation with the CRISPR 
endoribonuclease Csy4.RNA 21: 1921-1930. 
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results support the idea that the selective generation of the Csy4/hairpin complex 
resulting from cleavage of target mRNA might serve as a functional poly(A)/Poly-A 
Binding protein (PABP) surrogate, stabilizing the mRNA and supporting translation. 
Although the exact mechanism(s) remain to be determined, our studies expand the 
potential utility of CRISPR nucleases as tools for controlling mRNA stability and 
translation 
 
2.2 Introduction 
Endogenous control of gene expression is achieved by regulating transcription, 
processing, translation and/or degradation of mRNA through a myriad of genetic 
elements. Artificial control of gene expression, on the other hand, requires the 
development of small molecule, protein or RNA-based tools and is essential for 
advancing synthetic biology and gene therapies. Post-transcriptional regulation of gene 
expression has been achieved by engineering RNA, for instance by employing 
riboswitches that can not only be exploited to gain insight into endogenous RNA 
processing mechanisms, but also as programmable elements for building gene circuits 
(Chang et al., 2012). Another promising platform for developing RNA regulatory tools 
are the Pumilio/fem-3 binding factor or PUF proteins that recognize single stranded 
RNA in a sequence-specific fashion (Wang et al., 2013). PUF domains can be exploited 
to engineer splicing factors, control translation or develop artificial site-specific RNA 
endonucleases (Choudhury et al., 2012). Recent studies have suggested that bacterial 
CRISPR systems might be useful for RNA regulatory applications in comparison to the 
use of hammerhead ribozymes and RNase III (Qi et al., 2012). Regardless of the 
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approach, controlling RNA stability and translation is a key aspect underlying these 
gene regulatory strategies. 
The prokaryotic CRISPR (Clustered Regularly Interspaced Short Palindromic 
Repeats) system provides adaptive immunity against invading genetic elements in 
~45% of bacteria and ~83% of archaea (Grissa et al., 2007). Briefly, CRISPR loci 
encode a repeat-spacer array consisting of unique sequence elements (spacers), 
derived from previously encountered exogenous nucleic acid (Barrangou et al., 2007a; 
Bolotin et al., 2005; Mojica et al., 2005; Pourcel et al., 2005). Each spacer is flanked by 
repeat elements and the entire array is transcribed as a single pre-crRNA (Tang et al., 
2002; Tang et al., 2005). The pre-crRNA is processed into smaller crRNAs which serve 
as guides to target nucleic acid for neutralization by CRISPR-associated (Cas) proteins 
(Brouns et al., 2008; Garneau et al., 2010a). The protein content of CRISPR loci is 
diverse and as such, two broad classes of CRISPR systems have been described 
(Makarova et al., 2015). Classification is based on the utilization of either a single 
protein or a multi-subunit protein complex for target interference (Makarova et al., 
2015). These groups are further divided into types and sub-types denoted by roman 
numerals and alphabetical letters respectively. The Pseudomonas aeruginosa Class 1 
Type-IF CRISPR system employs Csy4 (Cas6f) to bind a 28-nucleotide repeat hairpin 
and cleave at the base of the 3' end to generate crRNAs (Cady and O'Toole, 2011; 
Haurwitz et al., 2010). The task of pre-crRNA processing in other systems falls to 
Cas5d, Cas6e (CasE/Cse3) and Cas6 in Bacillus halodurans, Escherichia coli and 
Pyrococcus furiosus respectively (Brouns et al., 2008; Carte et al., 2008; Nam et al., 
2012). 
23 
Structural studies have provided further mechanistic insight into pre-crRNA 
processing enzymes (Hochstrasser and Doudna, 2014). Despite their functional 
similarity, these enzymes display minimal primary sequence homology. Likewise, the 
sequences which they process also differ both in sequence and structure, with Cas5d, 
Cas6e, and Csy4 associated repeat elements containing hairpin structures and Cas6 
targeting a predicted unstructured sequence (Kunin et al., 2007). To carry out target 
neutralization, Csy4 remains bound to the processed crRNA and associates with 
additional Cas proteins, Csy1, Csy2, and Csy3 for target recognition (Wiedenheft et al., 
2011). This complex is guided to target DNA based on sequence complementarity 
provided by the crRNA. In Class 1 Type-I CRISPR systems, Cas3 is then recruited to 
cleave and degrade the target DNA, neutralizing the invader (Sinkunas et al., 2013; 
Westra et al., 2012). 
Recent studies have adapted the Class 1 Type-IF CRISPR endoribonuclease, 
Csy4 for processing of RNA encoding multigene operons and gene regulation in E. coli, 
Bacillus subtilis, and Saccharomyces cerevisiae (Qi et al., 2012). In particular, this study 
demonstrated that RNA processing by Csy4 is an effective strategy to maintain the 
endogenous function of different promoters, genes and regulatory elements without 
interference when engineered into complex genetic circuits. More recently, Csy4 has 
been applied for processing guide RNA (gRNA) for mammalian Cas9 technology and 
the programming of complex genetic circuits (Nissim et al., 2014; Tsai et al., 2014). 
These advancements have led to the expression of multiple gRNAs from a single 
promoter, removed the restriction of a 5' guanosine imposed by the U6 promoter, and 
permitted gRNA expression from RNA polymerase II promoters. Furthermore, Csy4 has 
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been utilized in the isolation of RNA-interacting proteins and has the potential to help 
analyze the protein-associations of diverse transcripts (Lee et al., 2013). In the current 
study, we systematically evaluated the ability of Csy4 to exercise post-transcriptional 
control of transgene expression in mammalian cells. Specifically, we investigate the 
positional effects of Csy4 mediated-cleavage in the 5' untranslated region (UTR), coding 
sequence, and 3'UTR of transcripts. Surprisingly, we find that the Csy4 processing of 
the 3' ends of mRNA supports translation and stabilizes the mRNA in lieu of a poly(A) 
signal. 
 
2.3 Materials and Methods 
Plasmids. The Csy4 gene was amplified from P. aerugionsa strain UCBPP-PA14 
genomic DNA and cloned under the control of the chicken beta-actin (CBA) promoter 
using the following primers: Csy4wt Forward 5'- ATC GTC TAG AAT GGA CCA CTA 
CCT CGA CAT TCG CTT GC-3' and Csy4wt Reverse 5'- CGA TGC GGC CGC TCA 
GAA CCA GGG AAC GAA ACC TCC TTT GC-3' (IDT DNA Technologies). P. 
aeruginosa UCBPP-PA14 genomic DNA was kindly provided by Dr. Matthew Wolfgang 
(University of North Carolina at Chapel Hill). Csy4-H29A was amplified from pHMGWA-
Pa14Csy4H29A (Addgene plasmid #41092) which was provided as a gift from Dr. 
Jennifer Doudna (Haurwitz et al., 2010). Csy4-H29A was cloned under the control of the 
CBA reporter. Csy4 R115A/R119A was synthesized as a gBlock ® (IDT DNA 
Technologies) and cloned under the control of the CBA promoter.  
The reporter plasmid constructs containing enhanced green fluorescent protein 
(GFP) and Gaussia luciferase (GLuc) were modified to incorporate the Csy4 hairpin 
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(HP) in different locations as follows. (i) Reporter cassettes containing the HP after the 
start codon (ATG-HP) were generated using overlap extension PCR with primers that 
generated two fragments containing a single, in-frame Csy4 HP repeat sequence (5'-
AGTTCACTGCCGTATAGGCAGCTAAGAAAT-3') in the 3' or 5' end. The two fragments 
were then gel purified and combined in equimolar quantities (40ng each) in consecutive 
PCR reactions without primers (35 cycles) and with flanking primers (30 additional 
cycles) to obtain the ATG-HP construct. The latter PCR products were then cloned 
under the control of the CBA promoter. (ii) The 5'UTR-HP-GFP was constructed by 
overlap extension PCR in a similar fashion, while the 5'UTR-HP-GLuc was synthesized 
as a gBlock ® (IDT DNA Technologies) and cloned under the control of the CBA 
promoter. (iii) 3'UTR-HP reporters and poly-A deleted 3'UTR-HP (3'UTR-HP-Δp(A)) 
reporters were synthesized from gBlocks® and cloned as described earlier. The cGFP-
mMALAT1-3' reporter was generously provided by Dr. Jeremy Wilusz (University of 
Pennsylvania). A partial Csy4 hairpin (5'-GTT CAC TGC CGT ATA GGC AG-3') and 
mascRNA were synthesized as a gblock ® (IDT DNA Technologies) and cloned in place 
of the mMALAT1 3' UTR in the cGFP-mMALAT1-3' reporter to generate cGFP-HP-
masc-Δp(A). Similarly, a second gblock ® (IDT DNA Technologies) was synthesized 
containing the partial Csy4 hairpin and mascRNA separated by 10 nucleotides (5'-CTA 
AAC GCG T-3') and cloned as described earlier, to generate cGFP-HP10-masc-Δp(A). 
 
Cell culture. HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(GIBCO/Life Technologies) supplemented with 10% FBS (Atlanta Biologicals), 1% 
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Penicillin/Streptomycin and 2.5 μg/mL amphotericin B (Sigma-Aldrich) and maintained 
at 37˚C and 5% CO2. 
 
Transfection and luciferase reporter assays. Equimolar amounts (totaling 500ng) of 
three plasmids (different HP GLuc reporters, Csy4 and a control plasmid containing the 
tdTomato reporter driven by the CBA promoter) were transfected into HEK293 cells 
using PEI Max seeded at a density of 5x104 per well in a 24 well plate. Media (50 μl) 
was collected from each well at different time intervals and diluted (1:100) before 
assessing luciferase reporter activity. For measuring GLuc activity, native 
coelenterazine (Nanolight) was dissolved in methanol to a concentration of 1 mg/mL 
and diluted (1:200) in 600 mM NaCl-Tris-EDTA buffer, following which, 50 μl of the 
substrate solution was added to 50 μl of collected media. Luminometric analysis was 
carried out using a Perkin Elmer Victor 3 ® plate reader. 
 
Fluorescence microscopy. HEK293 cells were transfected with different HP GFP 
reporter cassettes as described earlier and the cells imaged at different time intervals 
post-transfection using an EVOS ® FL epifluorescence cell imaging system (AMC/Life 
Technologies) using the GFP light cube (excitation 470nm, emission 510nm). 
 
mRNA analysis. Processing of mRNA was analyzed by monitoring the levels of DNA 
obtained through reverse transcriptase (RT) PCR. Briefly, HEK293 cells seeded 
overnight in 6 well plates at a density of 3x105 per well were transfected with a total of 
2.5μg of different plasmids (HP GFP reporters, Csy4wt or tdTomato control) as outlined 
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earlier. Total RNA from each well was isolated at 48 hours post-transfection using the 
Total RNA Purification Kit (#17200, Norgen Biotek). The purified RNA was then treated 
with DNase using the Turbo DNA-free kit (Ambion/Life Technologies). Equal ng 
amounts of the purified total RNA product were utilized as template for reverse 
transcriptase PCR using the High Capacity RNA-to-cDNA kit (Applied Biosystems/Life 
Technologies). Products of this reaction were used as template for further PCR 
amplification with gene specific primers and visualized on an agarose gel. Forward 
primer for amplifying ATG-HP-GFP cDNA: 5'-GCC ACC ATG AGT TCA CTG CCG-3'; 
Forward and reverse primers for amplifying all other GFP reporter cDNAs 5'-GAA ATG 
TGA GCA AGG GCG AGG AGC-3'; 5'-GCG GAC TTG AAG AAG TCG TGC TGC-3'; 
Forward and reverse primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
cDNA: 5'-CCA CTC CTC CAC CTT TGA C-3'; 5'-ACC CTG TTG CTG TAG C-3'. 
 
Detection of poly-adenylated mRNA. HEK293 cells seeded overnight in 6 well plates 
at a density of 3x105 cells per plate were transfected with a total of 3 μg DNA as 
indicated. Prior to transfection, DNA was prepared by digestion with ClaI, BglII, and CIP 
(New England Biolabs) to remove the GLuc expression cassette from its backbone and 
to prevent interference from potential downstream cryptic poly(A) signals. At 24 hours 
post-transfection, RNA was harvested using Total RNA Purification Kit (#17200, Norgen 
Biotek) and DNase treated using the Turbo DNA-free kit (Ambion/Life Technologies). A 
total of 1.3 μg DNase-treated RNA was converted to cDNA using SMARTScribe reverse 
transcriptase (Clontech) according to the manufacturer’s protocol. An oligo dT20 primer 
was used to prime the reverse transcription reactions. Products of this reaction were 
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utilized as template for further PCR amplification with gene specific primers and 
visualized on an agarose gel. Forward and reverse primers for reporter cDNAs (GLuc) 
5'-CAA CTT CGC GAC CAC GGA TCT CG-3'; 5'-CGG CAG CCA CTT CTT GAG CAG 
G-3'. Forward and reverse primers for GAPDH are listed above.  
 
RNA immunoprecipitation. HEK293 cells seeded overnight in 15 cm plates at a 
density of 5x106 cells per plate were transfected with 10 ug of His6-Csy4-H29A and 10 
ug of ATG-HP-GFP plasmids. Cells were lysed 48 hours post-transfection and RNA 
immunoprecipitation (RNA-IP) was carried out using the Magna RIP RNA Binding 
Protein Immunoprecipitation Kit (Millipore) according to the manufacturer’s protocol (-
His6 antibody, ab18184, Abcam). Purified RNA was DNase treated using the Turbo 
DNA free kit (Ambion/Life Technologies) and cDNA was generated from treated RNA 
via the Peregrine method (Langevin et al., 2013). cDNA was used as template for PCR 
with GFP specific primers 5'-GCC ACC ATG AGT TCA CTG CCG-3'; 5'-GCG GAC TTG 
AAG AAG TCG TGC TGC-3' and PCR products were visualized on an agarose gel.  
 
Northern Blot. HEK293 cells seeded overnight in 10 cm plates at a density of 2.2x106 
cells per plate were transfected with a total of 6 μg DNA as indicated. RNA was purified 
using Trizol reagent (Invitrogen/Life Technologies) and treated with DNase using the 
Turbo DNA-free kit (Ambion/Life Technologies). 1 microgram of RNA was separated on 
a 4% polyacrylamide/8M urea gel and transferred to Hybond N+ membrane (GE 
Healthcare). To generate radiolabeled probe, cGFP was digested out of the cGFP-
MALAT1-3' backbone and used as template for the incorporation of radiolabeled CTP 
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via a Random Primed DNA Labeling Kit (Roche Diagnostics). Hybridization of 
radiolabeled probe to the membrane was carried out using Rapid-Hyb buffer (GE 
Healthcare).  
 
Western Blot. HEK293 cells seeded overnight in 6 well plates at a density of 3x105 
cells per plate were transfected with a total of 2.5 μg DNA as indicated. Lysates were 
recovered 48 hours post-transfection using Passive Lysis Buffer (Promega). Lysates 
were diluted 1:50 and separated on a 10% Bis-Tris gel. Blots were probed with mouse 
monoclonal anti-GFP antibody (1:000 dilution, Santa Cruz) or mouse monoclonal anti-
Actin (1:2000 dilution, Abcam) as primary antibody. Stabilized peroxidase-conjugated 
goat anti-mouse antibody (1:5000 dilution, ThermoScientific/Life Technologies) was 
used as secondary antibody. Blots were developed using SuperSignal West Femto 
substrate (ThermoScientific/Life Technologies).  
 
2.4 Results and Discussion 
Csy4-mediated knockdown of 5' UTR-hairpin (HP) and ATG-HP constructs. 
We first evaluated the effect of Csy4-mediated cleavage of the substrate HP 
incorporated within the 5' untranslated region (UTR) or HP inserted in-frame 
immediately following the start codon of reporter transcripts. To this end, we cloned the 
Csy4 target hairpin (Figure 4A) derived from the P. aeruginosa strain UCBPP-PA14 
CRISPR locus, upstream (5'UTR-HP) or immediately downstream (ATG-HP) of the 
initiator AUG in two separate reporter genes, GFP and Gaussia Luciferase (GLuc) and 
compared the activity of these constructs to the control cassettes lacking the Csy4 
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hairpin (Figure. 4B). The reporters were transfected into HEK293 cells with or without a 
plasmid expressing Csy4. While no change in mRNA levels was observed as indicated 
by random primed RT-PCR in the case of the control plasmid lacking the Csy4 HP 
substrate, we observed a marked decrease in the case of the 5'UTR-HP and the ATG-
HP templates (Figure 4C). This observation was supported by a decrease in GFP signal 
from the 5’UTR-HP and ATG-HP templates, but not the control substrate as assessed 
by fluorescence microscopy (Figure 4D). Moreover, there was a ~24-fold decrease in 
GLuc reporter transgene expression mediated by Csy4 for the 5'UTR-HP construct and 
a ~37-fold decrease in signal for the ATG-HP construct (Figure 4E). In contrast, the 
control cassette displayed a minimal change in gene expression in the presence of 
Csy4. It is important to consider that the ATG-HP approach results in the incorporation 
of a 10 amino acid residue peptide tag with the sequence SSLPYRQLRN into the GFP 
or luciferase proteins. Further, it should be noted that we also observed a significant 
decrease in GLuc reporter activity of the 5'UTR-HP reporter construct in comparison 
with the unmodified or ATG-HP GLuc construct, even in the absence of Csy4. This is 
likely due to decreased efficiency of translational initiation by incorporation of a RNA 
hairpin structure in the 5'UTR region (Babendure et al., 2006; Kozak, 1986; Kozak, 
1989). These results are consistent in part with studies in S. cerevisiae, B. subtilis, and 
E. coli (Qi et al., 2012). In summary, our results confirm that Csy4 is functional in 
mammalian cells and can process RNA in a highly selective fashion mediated by the 
cognate hairpin substrate. 
 
 
31 
Effect of placing the HP in the 3’UTR on Csy4-mediated knockdown. 
In contrast to insertions near the 5'UTR or the start codon, placement of the Csy4 
target HP following the stop codon and prior to the poly(A) signal (3'UTR-HP, Figure 5A, 
left column) resulted in only a modest decrease in mRNA levels (as indicated by 
random primed RT-PCR) and GFP expression, when co-expressed with Csy4 (Figures 
5B, 5C, left columns). Further, quantitation of GLuc reporter activity indicated only a 
~2.5 fold reduction in transgene expression upon treatment with Csy4 (Figure 5D, left 
column). However, there was a substantial reduction in poly-adenylated reporter RNA 
levels as measured by oligo-dT20 primed RT-PCR, consistent with mRNA cleavage by 
Csy4 (Figure 5E, left column). These results are particularly intriguing, since removal of 
the poly(A) signal is expected to destabilize mRNA.  
The latter observations might arise from the fact that following cleavage Csy4 
remains bound to the cognate HP substrate (Haurwitz et al., 2010), which in turn could 
protect the 3' end of the transcript from degradation, despite removal of the poly(A) tail. 
Since translation is only slightly reduced, the Csy4/RNA complex must also be 
compatible with translation. To test this hypothesis, we generated a second set of 
reporters identical to the 3'UTR-HP constructs, but lacking a poly(A) signal (3'UTR-HP-
Δp(A)) (Figure 5A, right column). As seen in Figure 5B (right column), due to the lack of 
an efficient 3’ processing signal, the 3'UTR-HP-Δp(A) constructs accumulate only a 
small amount of RNA. However, when co-expressed with Csy4, we observed an 
increase in mRNA levels by random primed RT-PCR, as well as an increase in GFP 
transgene expression (Figures 5B, 5C, right columns). As described earlier, we then 
assessed the poly-adenylation status of this reporter mRNA by generating reverse 
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transcribed cDNA using an oligo-dT20 primer. Regardless of the presence or absence of 
Csy4, 3'UTR-HP-Δp(A) reporter mRNA levels primed by oligo-dT20 appeared low 
relative to 3'UTR-HP (Figure 5E, right column). This is consistent with the 3'UTR-HP-
Δp(A) RNA lacking a poly(A) signal. Importantly, Csy4 co-expression does not alter the 
amount of poly-adenylated RNA detected. Furthermore, quantitation of GLuc activity 
revealed a 9-fold increase in signal with Csy4 co-expression relative to a control lacking 
Csy4 (Figure 5D). This corroborates the notion that Csy4 can potentially stabilize mRNA 
containing the HP substrate in the 3'UTR and support translation. 
 
Csy4 binding and cleavage are necessary for regulation of transgene expression. 
We next sought to determine whether Csy4 binding to the substrate HP alone 
was sufficient or if binding followed by enzymatic cleavage was essential for regulation 
of transgene expression. Specifically, we used two mutants of Csy4; Csy4-
R115A/R119A, a binding deficient mutant that still retains catalytic activity, and Csy4-
H29A, a catalytically inactive, but binding competent mutant (Haurwitz et al., 2010; 
Sternberg et al., 2012).  
We first demonstrated Csy4 association with the target hairpin via RNA 
immunoprecipitation (RNA-IP). Hemagglutainin (HA)-tagged Csy4-H29A was expressed 
with the ATG-HP-GFP reporter and Csy4-RNA complexes were isolated from cell 
lysates using an -His6 antibody (Figure 6A). We were able to detect GFP RNA from 
the immunoprecipitates, indicating that Csy4 is interacting with the hairpin-tagged 
reporter RNA in mammalian cells (Figure 6B).  
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To evaluate the role of Csy4 binding and cleavage in regulating transgene 
expression, each reporter construct including the unmodified control, 5'UTR-HP, ATG-
HP, 3'UTR-HP and the 3'UTR-HP-Δp(A) reporter (Figure 7A) was expressed in the 
presence or absence of native Csy4, Csy4-H29A or Csy4-R115A/R119A. Expression 
from unmodified GFP and GLuc constructs was unaffected by either mutant. The 
5'UTR-HP GFP construct was also unaffected by co-expressing either the catalytically 
inactive or the binding deficient mutant (Figure 7B, 7D, 7E). Similar observations were 
made in case of the ATG-HP GFP reporter expressed with the catalytically inactive 
mutant, suggesting that steric hindrance from binding alone was insufficient to block 
translation initiation (Figure 7B, 7D). Further, the Csy4-R115A/R119A mutant also did 
not seem to substantially affect ATG-HP reporter expression (Figure 7B, 7E). Treatment 
with Csy4-H29A and Csy4-R115A/R119A did not dramatically affect expression of the 
corresponding GLuc reporters, supporting the previous data (Figure 7F). Taken 
together, these data suggest that both binding and cleavage are essential for Csy4-
mediated knockdown of transgene expression. In addition, neither mutant was able to 
rescue reporter signal in case of the 3'UTR-HP and the 3'UTR-HP-Δp(A) reporters 
(Figures 7B-F). These results support the notion that rescue of transgene expression 
from reporter constructs lacking a poly(A) tail requires both Csy4 binding to and 
cleavage of target mRNA. Thus, Csy4 bound to the cleaved hairpin at the 3' end of an 
mRNA appears to have the remarkable property of stabilizing the mRNA, translocating 
to the cytoplasm, and supporting translation.  
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Selective processing by Csy4 is essential for rescue of 3'UTR-HP-Δp(A) 
constructs. 
To further confirm the role of Csy4-mediated recognition and cleavage in 
rescuing 3'UTR-HP-Δp(A) reporters, we attempted to generate a similar cleaved 3' end 
product using a different endoribonuclease. Specifically, we engineered a novel reporter 
cassette (cGFP-HP-masc-Δp(A)), wherein a tRNA-like structure (mascRNA) was placed 
adjacent to the Csy4 HP (Figure 8A). This mascRNA motif is derived from the 3' end of 
a previously described MALAT1 RNA and is selectively cleaved by RNase P (Wilusz et 
al., 2008), releasing the capped 5' region of the transcript. In the endogenous MALAT1 
RNA, the 3' end generated by RNase P processing folds into a triple helix structure that 
is capable of stabilizing the RNA and supporting translation in the absence of a poly(A) 
signal (Brown et al., 2012; Wilusz et al., 2012). The cGFP-HP-masc-Δp(A) construct 
was engineered in such a manner that RNase P would cleave at the same nucleotide as 
Csy4, at the base of the Csy4 HP stem, releasing the mascRNA motif, but generating 
the same RNA product as Csy4 would generate. In addition, we also constructed a 
cassette, wherein the Csy4 HP and the mascRNA motif were separated by 10 
nucleotides to allow RNA processing at two different sites (Figure 8A, cGFP-cHP10-
masc-Δp(A)). In this construct, the initial RNaseP product can be subsequently cleaved 
by Csy4. A construct containing the full MALAT1 3’ end, including the 3' end stabilizing 
triple helix element in place of the Csy4 hairpin was used as a control (Figure 8A, 
cGFP-mMALAT1-3'). 
When transfected into HEK293 cells, cGFP-mMALAT1-3' reporter expression 
was not affected by co-expression with Csy4 wild type (Figures 8B, 8C). This is 
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expected due to the absence of a Csy4 target hairpin in this construct. In contrast, 
neither of the hairpin-containing reporters, cGFP-HP-masc-Δp(A) or cGFP-HP10-masc-
Δp(A), alone was able to support transgene expression due to the lack of a poly(A) 
signal or the MALAT1 triple helical motif (Figure 8B). However, co-expression of native 
Csy4 with these reporters rescued GFP expression, consistent with earlier results 
demonstrating the ability of Csy4 to stabilize the mRNA 3' end (Figure 8C). Northern 
blot using a cGFP probe confirmed these observations (Figure 8E). When expressed 
independently of Csy4, no cGFP RNA is detected for cGFP-HP-masc-Δp(A) or cGFP-
HP10-masc-Δp(A) (Figure 8E, lanes 2 and 4). However, when co-expressed with Csy4 
(lanes 3 and 5), a band is detected for each reporter that runs slightly below that of 
cGFP-mMALAT1-3' (Figure 8E, lane 1). This is expected as the cleavage products of 
cGFP-HP-masc-Δp(A) and cGFP-HP10-masc-Δp(A) are expected at 754 nt while the 
processed cGFP-mMALAT1-3' transcript runs at 844 nt. Our observations were further 
confirmed by western blot for cGFP on lysates expressing cGFP-mMALAT1-3' (lane 1), 
cGFP-HP-masc-Δp(A) (lane 2), or cGFP-HP-masc-Δp(A) with Csy4 (lane 3) (Figure 8F). 
Further, we expressed the cGFP-mMALAT1-3' construct, cGFP-HP-masc-Δp(A) or 
cGFP-HP10-masc-Δp(A) construct with the catalytically inactive Csy4-H29A mutant. In 
this setting, the reporter mRNA would only be processed by RNase P to generate a 3' 
end, however, Csy4-H29A is still expected to bind the HP substrate. As seen in Figure 
8D, while cGFP-mMALAT1-3' expression is unaffected, rescue of GFP transgene 
expression from both Csy4 HP-containing constructs using the catalytically inactive 
Csy4 mutant was markedly reduced. Interestingly, a few cells expressing GFP were still 
detectable, when Csy4-H29A was expressed with these reporter constructs. This 
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observation suggests that generation of a similar 3' end using RNase P in conjunction 
with binding by the Csy4-H29A mutant can at least partially rescue expression as seen 
with wild type Csy4. It should be noted that Csy4-mediated cleavage of the hairpin 
results in a 3'-phosphate at the base of the HP stem, while RNase P processing 
generates a 3'-hydroxyl group at the same position (Wiedenheft et al., 2011; Wilusz et 
al., 2008). A specific role for the 3’-phosphate group, if any, on Csy4-mediated rescue of 
non-polyadenylated RNAs is the subject of further exploration. Nevertheless, when 
taken together, these results affirm that both Csy4 binding and 3' end processing at the 
base of the HP stem are essential for stabilizing mRNA. 
 
Implications for studying and manipulating mRNA. 
Our studies suggest that Csy4 is a robust tool for knockdown of transgene-
derived mRNA. Potential applications for this versatile system include (i) post-
transcriptional control of transgenes, e.g., the development of ‘safety’ switches that can 
turn off gene expression (Di Stasi et al., 2011;Ketzer et al., 2014); (ii) spatio-temporal 
knockdown of over-expressed transgenes in animal models, where RNAi-mediated 
approaches to knockdown endogenous transgenes might not be effective; and (iii) 
multiplex processing of noncoding RNAs such as microRNAs without risking saturation 
of endogenous nucleus-to-cytosol transport machinery (Grimm et al., 2006). Another 
intriguing possibility is the potential to utilize different combinations of Class 1 Type I 
CRISPR endoribonucleases such as Cas6, Cas5d, Cas6e, and their corresponding 
substrates in multiplexed RNA processing applications (Brouns et al., 2008; Carte et al., 
2008; Nam et al., 2012). In addition to providing tools for controlling transgene 
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expression, the current studies might also help expand the application of CRISPR-
based tools for understanding RNA processing.  
Potential cellular processing events for 3'UTR constructs containing the Csy4 HP 
substrate and lacking a poly(A) signal (3'UTR-HP-Δp(A)) are shown (Figure 9). First, 
within the nucleus, poly(A)-deficient constructs are likely degraded by cellular 
exonucleases in the absence of Csy4 (steps (i) and (ii)). However, Csy4 binding (iii) 
followed by cleavage of the substrate (iv) appears to stabilize the mRNA and enable 
cytosolic transport as well as translation (v) by unknown mechanisms. It is well known 
that the poly(A) tail plays a multifunctional role in protecting mRNA from degradation, 
transcriptional termination, nuclear-to-cytosolic transport and translation. Thus, the 
absence of a poly(A) tail is generally associated with rapid mRNA degradation and a 
lack (or exceedingly low levels) of transgene product. In the current study, we clearly 
demonstrate the ability of Csy4 to stabilize such poly(A) deleted mRNA constructs 
subsequent to binding and processing of the substrate hairpin at the 3' end. Secondly, 
cytoplasmic export of the Csy4-bound transcript from the nucleus and translation are 
likely essential for rescuing transgene expression. The mechanisms underlying these 
critical events are currently under investigation. Similar paradigms have been proposed 
in relation to 3'UTR processing for two nuclear noncoding RNAs – MALAT1 and MEN 
beta, which form a triple helical structure capable of stabilizing transgene-derived 
mRNA, supporting nuclear export and translation (Wilusz et al., 2012). Other examples 
of such tertiary RNA structures have also been reported in case of histone and viral-
derived RNAs (Marzluff, 2012). For instance, Kaposi’s sarcoma associated herpesvirus 
(KSHV) is one such virus that employs an expression and nuclear retention element 
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(ENE) which also forms a triple helical structure (Mitton-Fry et al., 2010). Together, our 
studies and other examples in the literature strongly support the notion that the Csy4-
hairpin complex can potentially function as a surrogate poly(A) tail. From a broader 
perspective, our studies expand the potential utility of CRISPR nucleases as tools for 
controlling mRNA stability and translation.   
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Figure 4: Csy4-mediated knockdown of 5' UTR-hairpin (HP) and ATG-HP 
constructs. (A) Sequence of the Csy4 hairpin substrate and fragments after enzymatic 
cleavage. The cleavage site is indicated by a black triangle on the unprocessed hairpin. 
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(B) Schematics of the unmodified control (left), 5'UTR-HP (middle), and ATG-HP (right) 
reporters. (C) PCR products of randomly primed RNA isolated from HEK293 cells 
transfected as indicated. (Left) unmodified control, (middle) 5'UTR-HP-GFP and (right) 
ATG-HP-GFP. (D) Fluorescence images of HEK293 cells expressing unmodified control 
(left), 5'UTR-HP (middle), and ATG-HP GFP (right) reporters in the absence (-) or 
presence (+) of Csy4. Corresponding transmitted light images are shown as insets in 
each fluorescence image. (E) Quantitation of GLuc activity by luminometric analysis at 
24 hours post-transfection for unmodified control (left), 5'UTR-HP (middle), and ATG-HP 
(right), GLuc reporters. Error bars indicate standard deviation of four replicates. 
Statistical significance was calculated using a two-tailed Student’s t-test (****p≤0.0001). 
41 
 
Figure 5: Effect of placing the HP in the 3’UTR on Csy4-mediated knockdown. (A) 
Schematics of the 3'UTR-HP reporter (left) and 3'UTR-HP-Δp(A) reporter (right). (B) 
PCR products of randomly primed RNA isolated from HEK293 cells transfected with the 
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GFP-3'UTR-HP reporter (left) or GFP-3'UTR-HP-Δp(A) reporter (right) and Csy4 as 
indicated. (C) Fluorescence images of HEK293 cells expressing GFP-3'UTR-HP (left) or 
GFP-3'UTR-HP-Δp(A) (right) in the absence (-) or presence (+) of Csy4. Corresponding 
transmitted light images are shown as insets in each fluorescence image. (D) 
Quantitation of Gluc activity by luminometric analysis at 24 hours post-transfection for 
GLuc-3'UTR-HP (left) or GLuc-3'UTR-HP-Δp(A) (right) reporters. Error bars indicate 
standard deviation of four replicates. Statistical significance was calculated using a two-
tailed Student’s t test (****p≤0.0001). (E) PCR products of oligo-d(T)20 primed RNA 
isolated from HEK293 cells expressing GLuc-3'UTR-HP (left) or Gluc-3'UTR-HP-Δp(A) 
(right) with or without Csy4.  
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Figure 6: Cys4 interacts with the substrate hairpin in human cells. (A) Schematic 
representation of RNA immunoprecipitation (RNA-IP) detecting RNA associated with 
Csy4. An -His6 antibody is used to pull down His6-tagged Csy4-H29A and associated 
transcripts. (B) GFP-primed PCR products of cDNA generated from RNA purified from 
-His6 (Csy4-H29A) immunoprecipitates. Lysate from cells expressing ATG-HP-GFP 
and His6-Csy4-H29A served as RNA-IP input. Lanes are labelled as follows: reverse 
transcriptase (+RT), no reverse transcriptase (-RT), GFP plasmid positive PCR control 
(P), negative PCR control (H2O).  
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Figure 7: Csy4 binding and cleavage are necessary for regulation of transgene 
expression. (A) Schematics of reporters (left to right) - unmodified control, 5'UTR-HP, 
ATG-HP, 3'UTR-HP, and 3'UTR-HP-Δp(A). Fluorescence images of HEK293 cells 
expressing each reporter in the absence of Csy4 (B), or presence of either native Csy4 
(C), Csy4 H29A (D) or Csy4 R115A/R119A (E). Corresponding transmitted light images 
are shown as insets in each fluorescence image. (F) Quantitation of GLuc activity at 24 
hours post-transfection by luminometric analysis for each reporter. Error bars indicate 
standard deviation of four replicates. Statistical significance was expressed relative to 
the “No Csy4” control and calculated using a two-tailed Student’s t-test (****p≤0.0001, 
*** p≤0.001).  
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Figure 8: Selective processing by Csy4 is essential for rescue of 3'UTR-HP-Δp(A) 
constructs. (A) Schematics of the unmodified cGFP-mMALAT1-3' reporter (left), cGFP-
HP-masc-Δp(A) (middle)  and cGFP-HP10-masc-Δp(A) (right) reporters. Cleavage sites 
are indicated by black inverted triangles. Fluorescence images of HEK293 cells 
expressing either cGFP-mMALAT3' (left), cGFP-HP-masc-Δp(A) (middle), or cGFP-
HP10-masc-Δp(A) (right) in the absence of Csy4 (B), with Csy4 wild type (C), or Csy4-
H29A (D). Corresponding transmitted light images are shown as insets in each 
fluorescence image. (E) Northern blot of cGFP based reporters in the presence or 
absence of Csy4. cGFP-mMALAT1-3' (lane 1), cGFP-HP-mascΔp(A) (lane 2), cGFP-
HP-mascΔp(A) with Csy4 (lane 3), cGFP-HP10-masc-Δp(A) (lane 4), and cGFP-HP10-
masc-Δp(A) with Csy4 (lane 5). (F) A Western blot probing for cGFP using cell lysates 
of HEK293s expressing either cGFP-mMALAT1-3' (lane 1), cGFP-HP-mascΔp(A) (lane 
2), or cGFP-HP-mascΔp(A) with Csy4 (lane 3). A western blot for Actin is provided as a 
loading control.   
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Figure 9: Potential events outlining Csy4-mediated processing of 3'UTR-HP-Δp(A) 
mRNA. First, within the nucleus, poly(A)-deficient constructs are likely degraded by 
cellular exonucleases in the absence of Csy4 (steps (i) and (ii)). However, Csy4 binding 
(iii) followed by cleavage of the substrate (iv) appears to stabilize the mRNA and enable 
cytosolic transport as well as translation (v) by unknown mechanisms.  
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CHAPTER 3: INDUCING CIRCULAR RNA FORMATION USING THE CRISPR 
ENDORIBONUCLEASE CSY4 
3.1 Overview 
Circular RNAs (circRNAs) are highly stable, covalently closed RNAs that are 
regulated in a spatiotemporal manner. With wide-ranging functions, these molecules 
have the potential to be incorporated into engineered systems with broad technological 
implications. Here we describe a switch for activating backsplicing of an engineered 
circRNA that relies on the CRISPR endoribonuclease, Csy4, as an activator of 
circularization. The endoribonuclease activity and 3' end-stabilizing property of Csy4 are 
particularly suited for this task. Co-expression of Csy4 and the circRNA switch allows for 
the removal of downstream competitive splice sites and stabilization of the 5' cleavage 
product. This subsequently results in backsplicing of the 5' cleavage product into a 
circRNA that can efficiently translate a reporter protein from an internal ribosome entry 
site (IRES) element. Our switch reports RNA isoform status with red fluorescence 
indicating linear RNA, and green fluorescence signaling circRNA formation. Circular 
status is confirmed by RNase R digestion. We observe steady accumulation of circRNA 
products over the course of 96 hours in response to Csy4 co-expression. Ultimately, our 
platform outlines a straightforward approach towards regulating splicing and could find 
potential applications in synthetic biology as well as in studying the properties of 
different circRNAs. 
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3.2 Introduction 
Circular RNAs (circRNAs) comprise an emerging large class of noncoding, 
covalently closed RNAs present in a wide variety of organisms ranging from archaea to 
humans (Danan et al., 2012; Wang et al., 2014). They are typically generated through 
the covalent joining of a downstream splicing donor site with an upstream splicing 
acceptor site through a process called direct backsplicing (Jeck et al., 2013; Salzman et 
al., 2012). Due to their circular nature, circRNAs exhibit marked stability relative to their 
corresponding linear isoforms (Enuka et al., 2015; Jeck et al., 2013; Lasda and Parker, 
2014; Liang and Wilusz, 2014). The median half-life of circRNAs is at least 2.5X longer 
than their linear counterparts (Enuka et al., 2015). Furthermore, for some genes, the 
abundance of the circRNA exceeds that of the associated linear mRNA by a factor of 10 
(Jeck et al., 2013; Salzman et al., 2012).  
Despite their prevalence, the exact function of a large number of known 
circRNAs remains to be determined (Ebbesen et al., 2015). Functions appear to vary 
from circRNA to circRNA, highlighting the potential range of applications for engineered 
circRNAs. Some circRNAs such as ciRS-7 (Cdr1as) and the Sry circRNA appear to act 
as microRNA sponges, while circMbl has been proposed as a sponge for MBL protein 
(Ashwal-Fluss et al., 2014; Hansen et al., 2013; Memczak et al., 2013). Though most 
circRNAs arise from protein-coding exons, endogenously encoded circRNAs do not 
appear to be associated with ribosomes or translated (Capel et al., 1993; Guo et al., 
2014; Jeck et al., 2013). Engineered circRNAs can be translated, however, if an internal 
ribosome entry site (IRES) is included in the construct to drive translation (Chen and 
Sarnow, 1995; Wang and Wang, 2015). This property allows for expression of proteins 
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from stable, persistent RNA molecules. Accordingly, the development of molecular tools 
to exogenously control the circularization of a particular RNA of interest could prove 
useful.  
In this regard, an interesting RNA targeting enzyme that has garnered recent 
interest from the synthetic biology community is Csy4 (Cas6f). Csy4 is an 
endoribonuclease belonging to the Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR) family. CRISPR systems utilize small RNAs (crRNAs) to guide 
CRISPR nucleases to nucleic acid, mediating sequence specific cleavage (Marraffini, 
2015). Csy4 recognizes a 16 ribonucleotide hairpin which repeats throughout a 
precursor CRISPR RNA, cleaving at the 3' base of the hairpin stem to generate crRNAs 
(Cady and O'Toole, 2011; Haurwitz et al., 2010). Importantly, Csy4 remains associated 
with the 5' cleavage product (Sternberg et al., 2012). These properties of Csy4 have 
been adapted recently to process operon-encoding RNAs for gene expression without 
interference from cis sequences in E. coli, B. subtilis, and S. cerevisiae (Qi et al., 2012). 
Further, Csy4 was employed for processing RNA encoding multiple guide-RNA (gRNA) 
to single gRNAs for Cas9-based applications (Nissim et al., 2014; Tsai et al., 2014). 
Csy4 was also used to isolate and identify proteins associated with a specific RNA of 
interest (Lee et al., 2013). We recently demonstrated that Csy4 can be exploited to 
modulate the stability and subsequent protein expression of specific RNAs of interest 
(Borchardt et al., 2015). In particular, we demonstrated that Csy4 can stabilize the 
cognate 5’ cleavage product to allow translation of a reporter protein.   
Here, we take advantage of the latter property of Csy4 to induce circularization of 
RNA. CircRNA biogenesis is measured using a Csy4-dependent fluorescent reporter 
50 
system (circGFP-CD). This reporter may serve as a switch-based platform for the 
regulation of a variety of natural and engineered circRNA-mediated processes while 
also providing a new tool for shifting expression from one gene to another. Additionally, 
the Csy4-inducible circularization system has the potential for application in the study of 
factors involved in circRNA biogenesis.  
 
3.3 Materials and Methods 
Plasmids: The Csy4 gene was amplified from the pseudomonas aeruginosa UCBP-
PA14 genome using primers 5’-ATC GTC TAG AAT GGA CCA CTA CCT CGA CAT 
TCG CTT GC-3’ and 5’-CGA TGC GGC CGC TCA GAA CCA GGG AAC GAA ACC TC 
CTT TGC-3’. The PCR product was cloned under the control of the CBA promoter in a 
plasmid backbone. Csy4-H29A was amplified from pHMGWA-Pa14Csy4H29A 
(Addgene plasmid #41092) which was a gift from Dr. Jennifer Doudna (Haurwitz et al., 
2010). Csy4-H29A was cloned under the control of the CBA reporter. CircGFP was a 
gift from Dr. Zefeng Wang (Wang and Wang, 2015). To construct circGFP-CD, a gBlock 
® (IDT DNA Technologies) was synthesized consisting of the Csy4 targeted hairpin 
followed by the canonical intron 12 of IGF2BP1 and the P2A sequence in-frame with a 
dsRed coding sequence. This gblock was then cloned downstream of the split-GFP 
cassette such that the entire transcript is driven by the CMV promoter and terminated 
with a SV40 poly-A signal.  
 
Cell culture: HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(GIBCO/Life Technologies) supplemented with 10% FBS (Atlanta Biologicals), 1% 
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penicillin/streptomycin, and 2.5 μg/mL amphotericin B (Sigma-Aldrich) and maintained 
at 37⁰C and 5% CO2.  
 
Fluorescence microscopy and quantification of fluorescence: 5 X 104 HEK293 
cells were seeded overnight into 24 well plates and transfected with the indicated 
plasmids at equimolar quantities (500 ng). Cells were imaged at 72 hours post-
transfection using an EVOS FL epifluorescence cell imaging system (AMC/Life 
Technologies) with the GFP light cube (excitation 470 nm, emission 510 nm), or RFP 
light cube (excitation 530, emission 590). Three images were analyzed per replicate 
using the FIJI image processing package to measure integrated density (Schindelin et 
al., 2012). Values for all nine images were averaged. Error bars indicate standard 
deviation of integrated density calculated from nine images from three biological 
replicates (three images per replicate). Statistical significance was calculated using a 
two-tailed Student’s t-test ([****] P≤.0001, [*] P≤.05). 
 
RT-PCR: 3 X 105 HEK293 cells were seeded overnight into wells of a 6-well plate and 
transfected with the indicated plasmids at equimolar quantities (totaling 2500 ng). RNA 
was harvested from these cells 48 hours post-transfection using the Total RNA 
Purification Kit (Norgen Biotek) and DNase treated using the Turbo DNA-free kit 
(Ambion/Life Technologies). Equal nanogram amounts of DNase treated RNA was 
converted to cDNA using the High Capacity RNA-to-cDNA kit (Applied Biosystems/Life 
Technologies). Products of this reverse transcription reaction were utilized as template 
for PCR amplification using gene-specific primers for GFP (5'-AGT GCT TCA GCC GCT 
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ACC C-3', 5'-GTT GTA CTC CAG CTT GTG CC-3') and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (5'-CCA CTC CTC CAC CTT TGA C-3', 5'-ACC CTG TTG 
CTG TAG CC-3'). PCR products were visualized on an agarose gel. 
 
Western blot: HEK293 cells seeded overnight in 6 well plates at a density of 3 x 105 
cells per well were transfected with a total of 2 μg DNA as indicated. Lysates were 
recovered 48 hours post-transfection using 1X Passive Lysis Buffer (Promega) and 
diluted 1:10. Samples were heated to 100C before separation on a 10% Bis-Tris gel. 
Membranes were blocked overnight in 2% milk in TBST. After overnight incubation, 
membranes were blotted with primary antibody against either GFP (1:1000 Santa Cruz, 
SC9996) or Actin (1:2000, Abcam, Ab3280). Stabilized peroxidase-conjugated goat 
anti-mouse antibody was used as secondary antibody (1:20,000, Jackson 
Immunologicals, 31430). Blots were developed using SuperSignal West Femto 
substrate (Thermo Scientific/Life Technologies).  
 
RNaseR digestion: 2.2 X 106 HEK293 cells were seeded overnight into 10 cm plates 
and transfected with the indicated plasmids at equimolar quantities (totaling 6 
micrograms). RNA was harvested at 72 hours post-transfection via TRIzol Reagent 
(Invitrogen/ThermoFisher Scientific) according to the manufacturer’s protocol. 10 
micrograms of RNA was treated with 10 units of RNaseR (Epicentre) at 37C for 10 
minutes. Enzyme was inactivated at 95C for 5 minutes. The resulting RNA was subject 
to DNase treatment and RT-PCR as outlined above. Products were PCR amplified 
using primers detecting circular products (5'-CTG CTT GTC GGC CAT GAT ATA GAC 
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GTT GTG GC-3', 5'-CAA GCT GAC CCT GAA GTT CAT CTG CAC CAC C-3') or linear 
products (5'-CTT GGT CAC CTT CAG CTT GGC GGT CTG -3', 5'-GCT ACG TCC AGG 
GAT CCG GCG-3'). 
 
qRT-PCR: 3 X 105 HEK293 cells were seeded overnight into wells of a six-well plate. 
Before transfection, control RNA was harvested from cells using the Total RNA 
Purification Kit (#17200, Norgen Biotek). Remaining cells in separate wells were 
transfected with equimolar amounts (totaling 6 μg) of the indicated plasmids using PEI 
Max. RNA from each condition was harvested at time intervals of 8, 24, 48, 72 and 96 
hours post-transfection using the Total RNA Purification Kit (Norgen Biotek) and treated 
with DNase using the Turbo DNA-free kit (Ambion/Life Technologies). 250 ng of DNase 
treated RNA was converted to cDNA using the High Capacity RNA-to-cDNA kit (Applied 
Biosystems/Life Technologies). Products of this reaction were diluted 1:100 and used 
as template for qPCR.  qPCR was carried out using the Faststart Essential DNA Green 
Master Mix (Roche) and primers for detecting GFP (5'-AGT GCT TCA GCC GCT ACC 
C-3', 5'-GTT GTA CTC CAG CTT GTG CC-3'), dsRed (5'-GCT ACG TCC AGG GAT 
CCG GCG-3', 5'-CTT GGT CAC CTT CAG CTT GGC GGT CTG-3') or GAPDH (5'-CCA 
CTC CTC CAC CTT TGA C-3', 5'-ACC CTG TTG CTG TAG CC-3'). Data was analyzed 
using the ΔΔCt method and GFP and dsRed values are expressed relative to GAPDH 
values and normalized to t=0 control RNA. Error bars represent standard deviation of 
three biological replicates. Statistical significance was calculated using a two-tailed 
Student’s t-test ([****] P≤.0001, [***] P≤.001, [**] P≤.01, [*] P≤.05). 
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3.4 Results and Discussion 
To visualize the switch from linear to circular RNA products, we generated a 
dual-fluorescence reporter, circGFP-CD (Figure 10). The circGFP-CD reporter 
expresses dsRed upon forward splicing (linear RNA) and GFP upon backsplicing 
(circRNA). The reporter design was based on an circGFP construct reported earlier 
(Wang and Wang, 2015). Briefly, the original circGFP cassette consists of a split GFP in 
which the N terminal fragment of GFP lies downstream of the C terminal fragment. The 
C terminal fragment is preceded by a canonical splice acceptor sequence while the N 
terminal fragment is immediately followed by a canonical splicing donor sequence. The 
two fragments are separated by an IRES sequence such that, upon backsplicing, full 
length GFP is reconstituted and can be expressed as protein. Further, the split-GFP 
cassette is flanked by intron sequences which have been engineered to base pair in 
order to facilitate circularization (Wang and Wang, 2015). In the current study, we added 
an intron and competing splice acceptor site downstream from the split-GFP cassette. 
The splice acceptor is followed by a P2A-dsRed cassette, where the P2A peptide signal 
disrupts translation, while simultaneously allowing dsRed expression without being 
directly fused to GFP (Szymczak and Vignali, 2005). To toggle from linear RNA to 
circRNA, the split GFP and P2A-dsRed cassettes were separated by a Csy4 substrate 
hairpin (circGFP-CD; Figure 10A). Expression of circGFP-CD in the absence of Csy4 
should favor forward splicing and result in dsRed expression (Figure 10A). Conversely, 
when circGFP-CD is co-expressed with Csy4, we expect the competing splice acceptor 
and P2A-dsRed encoding sequence to be cleaved away, leaving behind the 5' splice 
acceptor site (Figure 10B). We then hypothesized that the stabilization of the 5' 
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cleavage product by Csy4 could permit the cleaved split-GFP RNA to persist long 
enough for back-splicing to occur and support GFP expression (Figure 10B).  
We first tested the circGFP-CD construct following plasmid transfection in 
mammalian cells and observed reporter expression via fluorescence microscopy. 
CircGFP, which is constitutively backspliced for GFP expression, is included as a 
control (Figure 11). When circGFP-CD is expressed alone, forward splicing appears to 
be favored as the cells strongly express dsRed but lack GFP fluorescence (Figure 11A). 
This expression pattern is consistent with predominant forward splicing and minimal 
backsplicing. It is important to note that the forward splice acceptor is identical to the 
backsplice acceptor in sequence. Therefore, the abundance of dsRed signal indicates 
that forward splicing is favored over backsplicing in this intron/exon configuration and 
host cell type. In contrast, when Csy4 is co-expressed with circGFP-CD, dsRed signal 
decreases while pronounced GFP signal appears, consistent with activation of circRNA 
biogenesis (Figure 11A). Fluorescence was quantified using FIJI image processing 
software (Schindelin et al., 2012) and the decrease in dsRed signal upon co-expression 
with Csy4 was measured at -6 fold. The corresponding increase in GFP signal was 
measured at +116 fold relative to Csy4 absent conditions (Figure 11B, 11C). The 
appearance of GFP signal concurrent with diminishing dsRed signal is consistent with 
Csy4 cleaving away the P2A-dsRed element and stabilizing the 5’ cleavage product. 
This allows back-splicing and subsequent GFP expression to occur.  
To confirm that RNA cleavage and removal of the forward splicing acceptor is 
essential for favoring back-splicing, we co-expressed circGFP-CD with a catalytically 
dead Csy4 mutant, Csy4-H29A (H29A). This mutant is capable of binding to the target 
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hairpin, but is unable to cleave the RNA (Haurwitz et al., 2010). In the presence of 
H29A, GFP signal did not increase to the levels observed with native Csy4 (Figure 
11A). This is consistent with Csy4 cleavage being required for predominant backsplicing 
to occur. However, when quantified, GFP signal did increase slightly by 1.8 fold (Figure 
11C). Interestingly, H29A co-expression also induced a 2.4 fold increase in dsRed 
signal relative to Csy4 absent conditions (Figures 11A, 11B).  
 We then characterized the different RNA species generated from circGFP-CD 
using PCR and RNase R treatment. Two PCR primer sets were designed for the 
detection of either circular or linear products. The primers for circRNA detection will only 
result in product when the GFP fragments have been spliced into the appropriate 
orientation, for example, via RNA circularization. In the absence of Csy4, a faint band 
was detected using circular detection primers, indicating that back-splicing from 
circGFP-CD RNA occurs at a low basal rate (Figure 12A). However, when circGFP-CD 
RNA is co-expressed with Csy4, a robust signal is detected, demonstrating an increase 
in circRNA levels (Figure 12A). A modest increase in circRNA levels was also observed 
upon co-expression with H29A (Figure 12A). This increased detection of circRNA is 
consistent with fluorescence data shown earlier (Figure 11C). Together, these results 
demonstrate a slight improvement in overall splicing in the presence of Csy4-H29A. 
This effect may result from H29A-mediated RNA stabilization, although further studies 
will need to be conducted to fully elucidate the potential mechanism. Still, western blot 
analysis demonstrated that detectable amounts of GFP protein were only observed 
when circGFP-CD RNA was co-expressed with native Csy4 (Figure 12B). These results 
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corroborate the requirement of Csy4 for circularization and consequently GFP 
expression in our reporter system.  
We further confirmed circRNA production by RNase R digestion. RNase R is a 3'- 
to 5'- exonuclease to which circRNAs are inherently resistant due to their lack of a 3’ 
end (Suzuki et al., 2006). RNA derived from circGFP, which is constitutively back-
spliced into circRNA, is included as a control and yields an RNase R resistant product 
(Figure 12C). When circGFP-CD RNA was expressed in the absence of Csy4, RNA was 
primarily detected using primers against linear template and was susceptible to RNase 
R (Figure 12C). This is consistent with predominant forward splicing in the absence of 
Csy4. Detection of RNase R susceptible linear product decreased when RNA from cells 
co-expressing Csy4 with circGFP-CD was analyzed (Figure 12C). Under these 
conditions, an RNase R resistant product was observed using primers designed for 
circRNA detection (Figure 12C). These results are consistent with Csy4-activated 
circRNA production. Taken together, these data indicate that the predominant splicing 
product of circGFP-CD switches from linear to circular when co-expressed with Csy4.  
 To observe the kinetics of circRNA formation from the circGFP-CD construct, we 
measured RNA levels over time by qRT-PCR. CircRNA and forward splicing products 
were differentiated by primers designed against circular and linear splicing products as 
depicted in Figure 13. Consistent with earlier studies, we observed circGFP control 
circular RNA levels rising over the course of 72 hours (Wang and Wang, 2015) (Figure 
13B). Accumulation of circRNA from cells co-transfected with circGFP-CD and Csy4 
also increased over time in a manner similar to circGFP (Figure 13B). This observation 
suggests that modulating circRNA formation with Csy4 might not affect efficiency of 
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circRNA synthesis. Importantly, in the absence of Csy4, circRNA levels remained low 
when expressed from the circGFP-CD cassette (Figure 13B). We next performed qRT-
PCR with primers detecting forward splicing products (Figure 13A). Forward splicing 
products were expressed at high levels in case of the circGFP-CD without Csy4 (Figure 
13A). Consistent with imaging and RNaseR studies, circGFP-CD co-transfected with 
Csy4 also expressed low levels of forward splice products. However, expression of 
these products remained consistently low relative to circGFP-CD transfected alone 
(Figure 13A). These results may indicate that a small proportion of RNA expressed from 
circGFP-CD is forward spliced before Csy4 cleaves away the forward splice acceptor.  
In conclusion, we have designed a CRISPR-based, inducible system for 
circularization of RNA in mammalian cells. Csy4 acts as a reliable regulatory part for 
controlling the circGFP-CD switch, activating circRNA biogenesis, and protein 
expression.  Likewise, CircGFP-CD is an adaptable device for the expression of a 
variety of proteins or functional non-coding RNA sequences for use in genetic circuits.  
A wide variety of RNA-based tools have been engineered for manipulating gene 
expression (Liang et al., 2011). For example, riboswitches and ribozymes are popular 
ligand responsive tools for controlling gene expression at the RNA level (Groher and 
Suess, 2014). Other tools for controlling RNA splicing include Engineered Splicing 
Factors (ESFs) (Wang et al., 2009). ESFs may serve as alternative options for 
regulating backsplicing efficiency. Here, we expand the RNA toolkit by developing a 
Csy4-dependent circRNA platform that provides a unique approach to regulate splicing, 
RNA stability, and protein translation. The functional utility of this inducible circRNA 
platform could potentially be expanded by replacing the fluorescent reporter ORFs with 
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other functional components. Such components include miRNA or protein sponge 
sequences as well as ORFs of proteins of interest. While the current system enables 
toggling from linear to circular RNA using Csy4, it might be possible to further optimize 
this system with the addition of cis-acting sequences and target sequences for trans-
acting factors that have been shown to favor circRNA formation (Ashwal-Fluss et al., 
2014; Conn et al., 2015; Ivanov et al., 2015; Jeck et al., 2013; Kramer et al., 2015; 
Liang and Wilusz, 2014; Zhang et al., 2014). As a circRNA expression tool, the addition 
of inverted repeat sequences known to facilitate circularization could improve the back-
splicing efficiency of the reporter circRNA. In addition to temporal regulation, it might be 
possible to regulate circRNA expression in a cell/tissue-specific manner by changing 
promoter elements. Ultimately, CRISPR-induced circRNA formation could serve as a 
versatile platform for a range of potential applications in synthetic biology. 
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Figure 10: Schematic of circGFP-CD splicing patterns and reporter outputs. The 
mRNA expressed from circGFP-CD contains a split-GFP cassette flanked by 
engineered introns (intron and intron’). This cassette is followed by a Csy4 targeted 
hairpin, another intron and a P2A-dsRed cassette. Splice sites are represented by grey 
triangles and the dotted line indicates the expected predominant splicing pattern. In the 
absence of Csy4 (A), forward splicing is favored and an IRES drives expression of 
dsRed. A non-fluorescing GFP fragment by-product is released via the P2A sequence. 
In the presence of Csy4 (B), Csy4 cleaves the RNA at the base of the hairpin stem, 
releasing the forward splice acceptor and P2A-dsRed cassette. Csy4 remains 
associated with the cleaved hairpin, stabilizing the RNA and allowing back-splicing to 
occur. The IRES subsequently drives full length GFP expression from the circular RNA.   
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Figure 11: Csy4 induces circGFP-CD reporter expression to switch from dsRed to 
GFP.  (A) Representative images of dsRed (top) and GFP (bottom) fluorescence from 
HEK293 cells expressing circGFP control (far left), or circGFP-CD in the absence of 
Csy4 (middle left), presence of native Csy4 (middle right) or presence of Csy4-H29A 
(far right) 72 hours post-transfection. Schematics of expected RNA species pre-splicing 
are depicted above each image column for each condition while schematics of expected 
RNA species post-splicing are depicted on the left of each row. Quantification of dsRed 
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(B) and GFP (C) fluorescence from images taken 72 hours post-transfection of HEK293 
cells using the FIJI image processing package (Schindelin et al., 2012). Error bars 
indicate standard deviation of integrated density calculated from nine images from three 
biological replicates (three images per replicate). Statistical significance was expressed 
relative to the circGFP-CD “-Csy4” control and calculated using a two-tailed Student’s t-
test ([****] P≤.0001, [*] P≤.05). 
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Figure 12: Detection of circGFP-CD expression products. Primers designed against 
either circular RNA or linear RNA products are depicted in each panel. (A) PCR 
products obtained using cDNA template generated from randomly primed RNA that was 
isolated from HEK293 cells transfected as indicated. GAPDH PCR products were 
amplified as loading controls from the same templates. (B) Western blot detecting GFP 
or loading control Actin for lysates of HEK293 cells transfected as indicated. (C) PCR 
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products amplified using primers specific for linear or circular splicing patterns. 
Template cDNA was generated using RNA isolated from HEK293 cells transfected with 
either circGFP, circGFP-CD, or circGFP-CD and Csy4 and treated with RNaseR as 
indicated.  
  
6
5
  
Figure 13: Accumulation of circRNA and linear splicing products over time. qRT-PCR of cDNA generated from RNA 
isolated at 8, 24, 48, 72, and 96 hours normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and 0 hour 
transfection controls. Cells were transfected with either circGFP-CD (open circles, dotted line), circGFP-CD and Csy4 
(closed circles, solid line), or with a circGFP control plasmid (open triangles, solid line). qRT-PCR was carried out using 
primers specific for either linear (A) or circular (B) splicing products as depicted above each graph. Error bars indicate 
standard deviation of three biological replicates. Statistical significance for the “circGFP-CD + Csy4” condition was 
expressed relative to “circGFP-CD” and was calculated using a two-tailed Student’s t-test ([****] P≤.0001, [***] P≤.001, [**] 
P≤.01, [*] P≤.05). 
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CHAPTER 4: IN VIVO DELIVERY OF TRANSLATABLE CIRCULAR RNA 
CASSETTES USING RECOMBINANT AAV VECTORS 
4.1 Overview 
 Circular RNAs (circRNAs) are highly stable, persistent RNAs which serve a wide 
variety of cellular roles. With broad utility and potential for long-lasting effects due to 
their stability, circRNAs possess great promise as therapeutic agents. As currently 
understood, the natural functions of circRNAs are non-coding. However, circRNAs can 
be engineered for protein expression by the inclusion of an Internal Ribosome Entry Site 
(IRES) to drive translation. Recombinant Adeno-Associated Virus (rAAV) is commonly 
utilized in the field of gene therapy for the delivery of therapeutic cassettes. rAAV is an 
ideal candidate for transgene delivery due to well-defined tropism and minimal genome 
packaging requirements. Still, dose-related toxicity requires careful consideration when 
utilizing rAAV for therapeutic applications. Means to lower vector dosage while 
expressing gene products at therapeutic levels would alleviate some concern. With 
pronounced stability and long-term persistence, circRNAs are poised for maintaining 
long-term gene expression. This quality could prove essential for lowering effective 
vector dosage. Here we demonstrate expression of a circRNA reporter in mice through 
rAAV-mediated gene delivery. Unlike naturally occurring circRNAs, our reporter circRNA 
expresses a protein (GFP) through the inclusion of an IRES sequence. The GFP coding 
sequence is split such that full length GFP is only expressed upon RNA circularization. 
When administered via rAAV vectors, we observed GFP expression in the mouse heart 
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and liver. CircRNA biogenesis was confirmed via RNase R digestion. These results 
provide the foundation for AAV-mediated delivery of circRNA cassettes for a variety of 
therapeutic applications.  
 
4.2 Introduction 
Circular RNAs (circRNAs) comprise a class of covalently closed, exceedingly 
stable non-coding RNAs (ncRNAs). Initially overlooked as splicing byproducts, 
circRNAs are now recognized as highly abundant molecules with unique and complex 
expression patterns (Memczak et al., 2013; Salzman et al., 2012; Salzman et al., 2013) 
CircRNAs are found throughout the tree of life, with representation in organisms ranging 
from archaea, yeast, and amoeba, to more complex systems such as  Caenorhabditis 
elegans, Drosophila melanogaster, and humans (Danan et al., 2012; Memczak et al., 
2013; Salzman et al., 2013; Wang et al., 2014). The persistence of circRNAs throughout 
this wide range of organisms highlights the importance of these RNAs. It additionally 
supports further investigation into their biogenesis, function, and potential applications. 
CircRNA biogenesis is thought to utilize a mechanism called backsplicing in 
order to join a downstream splicing donor to an upstream splicing acceptor. (Jeck et al., 
2013). However, an alternate mechanism which employs a lariat intermediate has also 
been proposed (Zaphiropoulos, 1996).  
CircRNAs are inherently stable and persistent, likely as a consequence of 
reduced exonucleolytic degradation resulting from their lack of exposed ends. The 
stability of circRNAs is demonstrated by a median half-life at least 2.5X longer than that 
of their linear counterparts (Enuka et al., 2015). In some cases, circRNAs outnumber 
 68 
their associated linear RNAs by a factor of 10 (Jeck et al., 2013; Lasda and Parker, 
2014).  
Though the abundance of circRNAs has been well established, the roles of most 
circRNAs remain undetermined. However, from the few circRNAs with well-
characterized functions, it is clear that circRNAs possess wide regulatory capacity. The 
circRNA Cdr1as (ciRS-7) acts as a miRNA sponge by interacting with miR-7 through 63 
conserved miR-7 binding sites (Hansen et al., 2013; Memczak et al., 2013). Similarly, 
circSry also acts as a microRNA (miRNA) sponge by binding to miR-138 (Hansen et al., 
2013). CircHIPK3 is an example of a circRNA capable of binding multiple different 
miRNAs and interacts with nine miRNAs over 18 binding sites (Zheng et al., 2016). 
CircMBL, on the other hand, is an example of a circRNA that binds protein. In an 
autoregulatory fashion, circMBL interacts with the MBL (Muscleblind) protein (a product 
of the MBL linear RNA), through MBL binding sites. This in turn regulates circMBL 
formation, which relies on MBL protein (Ashwal-Fluss et al., 2014).  
The miRNA and protein sponging activity of circRNAs could affect a number of 
downstream processes. In one example, circFoxo3 binds to the cell cycle regulators 
p21 (cyclin dependent kinase inhibitor 1) and CDK2 (cyclin dependent kinase 2) (Du et 
al., 2016b). This interaction sequesters CDK2 from interacting with additional cell cycle 
proteins cyclin A and cyclin E, effectively preventing cell cycle entry (Du et al., 2016b). 
Similarly, circHIPK3 interacts with growth suppressive miRNAs. By binding these 
miRNAs, circHIPK3 is able to promote cell proliferation (Zheng et al., 2016). Additional 
proposed functions for circRNAs include transcription regulation and pseudogene 
formation (Dong et al., 2016; Li et al., 2015). 
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It is clear from their extensive breadth of innate functions, that circRNAs may 
provide a basis for number of therapeutic applications. Beyond their natural roles, 
circRNAs can be engineered for expressing proteins, provided that an Internal 
Ribosome Entry Site (IRES) is included for initiating translation (Chen and Sarnow, 
1995; Wang and Wang, 2015). Further, in the previous chapter, we demonstrated that 
circRNA formation can be regulated by the CRISPR protein Csy4. The stability and 
utility of circRNAs thus provides and attractive platform for therapeutic gene expression 
of both protein and non-coding effectors.  
Adeno-Associated Virus (AAV) is a helper-dependent parvovirus which is 
commonly adapted for applications in gene therapy and gene delivery (Samulski and 
Muzyczka, 2014). A number of natural and engineered AAV serotypes have been 
thoroughly characterized with well-defined tropisms (Asokan et al., 2012; Asokan and 
Samulski, 2013; Murlidharan et al., 2014). Further, The AAV genome can easily be 
tailored for delivery of nearly any cassette of interest provided it meets two 
requirements. First, the cassette must be flanked by AAV inverted terminal repeat 
sequences (ITRs) which are necessary for AAV genome packaging. Second, the vector 
genome must fit within the AAV packaging capacity of 4.7 kb. In addition, AAV’s lack of 
pathogenicity and inability to replicate independently make recombinant AAV (rAAV) 
vectors excellent tools for gene delivery.  
In this study, we demonstrate rAAV-mediated delivery of circRNA cassettes in 
mice. Further, we show that circRNAs can be translated in vivo to produce protein. Our 
findings can ultimately be applied towards the therapeutic design and usage of circRNA 
cassettes as both non-coding RNAs and for protein expression. 
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4.3 Methods 
Plasmids. A split-GFP plasmid was provided as a generous gift from Dr. Zefeng Wang. 
To generate circGFP, the entire CMV-splitGFP-poly(A) sequence was PCR amplified 
out of the split-GFP cassette. The PCR product was subsequently cloned into an AAV 
vector ITR backbone for viral packaging. IRES-GFP was generated by overlap-
extension PCR to join the IRES sequence with full length GFP. Fragments with 
overlapping GFP sequence were PCR amplified using the circGFP plasmid as template. 
The fragments were gel purified and combined in equimolar quantities (40 ng each) in 
consecutive PCR reactions without primers (35 cycles) and with flanking primers (29 
additional cycles).  The PCR product was cloned into the circGFP AAV vector backbone 
directly following the CMV promoter and before the poly(A) signal.  
 
Cell culture. HEK293 cells were cultured in Dulbecco’s Modified Eagle’s Medium 
(GIBCO/Life Technologies) supplemented with 10% FBS (Atlanta Biologicals), 1% 
penicillin/streptomycin, and 2.5 μg/mL amphotericin B (Sigma-Aldrich) and maintained 
at 37⁰C and 5% CO2.  
 
Detection of the circGFP splicing junction. HEK293 cells were seeded at a density of 
3x105 per well in a 6 well plate 24 hour prior to transfection. One microgram of circGFP 
plasmid was transfected into cells using PEI Max. Purified RNA was isolated using the 
Total RNA Purification Kit (#17200, Norgen) 72 hours post-transfection. RNA was 
treated with DNase using the Turbo DNA-free kit (Ambion/Life Technologies). DNase 
treated RNA was converted to cDNA using the High Capacity RNA-to-cDNA kit (Applied 
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Biosystems/Life Technologies). cDNA product was used as template for PCR 
amplification of full length GFP using primers (5’-GTA CAG CTC GTC CAT GCC GAG 
AGT GAT CC-3’, and 5’-AGC AAG GGC GAG GAG CTG TTC ACC-3’). The PCR 
product was visualized on an agarose gel, gel purified, and Sanger sequenced (Eton 
Biosciences).  
 
Recombinant AAV vector production. Recombinant AAV vectors were generated by 
a triple-plasmid transfection protocol (Shen et al., 2013a). Briefly, plasmid containing 
ITR flanked expression cassettes, a pXR9 helper plasmid, and a pXX6-80 adenoviral 
helper plasmid were transfected into HEK293 cells. After 72 hours, media was 
harvested off of these cells and subjected to vector purification by iodixanol gradient 
centrifugation. Fractioned virus was concentrated using a Pierce Concentrator (MWCO 
150K, Thermo Scientific). Virus was then titered by qPCR using a Roche Lightcycler 96 
(Roche Applied Sciences) with primers specific for the AAV2-ITR (5′-AAC ATG CTA 
CGC AGA GAG GGA GTG G-3′; 5′-CAT GAG ACA AGG AAC CCC TAG TGA TGG 
AG-3′) (IDT Technologies). 
 
Intraperitoneal injections. BALB/c were mice bred and maintained in accordance with 
NIH guidelines and as approved by the University of North Carolina (UNC) Institutional 
Animal Care and Use Committee (IACUC). Neonatal postnatal day 2 (P2) pups were 
anesthetized by hypothermia by placement on ice for two minutes prior to injection. 
Mice were injected intraperitoneally with a dose of 5.75 X 1010 vector-genome 
containing particles (volume of 25 uL) of rAAV9 packaging the indicated virus. After 
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injection, mice were revived under a heat lamp, rubbed in bedding, and placed back 
with their mother. 5.5, 10, and 16 weeks post-injection, heart and liver were harvested 
from each mouse, post-fixed in paraformaldehyde, sectioned, and immunostained as 
described below. 
 
Tissue processing and 3,3’-Diaminobenzidine (DAB) immunohistological 
analysis. Mice were sacrificed at the indicated timepoints with an overdose of 
tribromoethanol (Avertin) (0.2 mL of 1.25% solution) and subsequent transcardial 
perfusion of 4% paraformaldehyde in PBS. Heart and liver were removed and post-fixed 
overnight in 4% paraformaldehyde and then sectioned into 50-micron sections using a 
Leica VT 1200S vibrating blade microtome (Leica Biosystems). To stain, sections were 
blocked in 1% Triton X 100 and 10% goat serum in PBS, followed by overnight 
incubation with primary monoclonal antibody against GFP at a dilution of 1:750 (Life 
Technologies, G10362). Following overnight incubation, sections were washed with 
PBS and staining continued using the Vectastain ABC kit (Rabbit IgG, Vector 
Laboratories) according to the manufacturer’s protocol. Stained sections were mounted 
onto slides and then visualized via light microscopy using an Evos FL epifluorescence 
cell imaging system. Slide scans were obtained by the UNC Translational Pathology 
Laboratory. Slide scan images were acquired using a bright field Aperio ScanScope XT 
and analyzed using Aperio ImageScope software. 
 
Western blot. 10 tissue sections for each condition (CMV-GFP, IRES-GFP, or circGFP) 
at the 10-week timepoint were disrupted in 1X Passive Lysis Buffer (Promega) using a 
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TissueLyser (Qiagen). Disrupted tissue was incubated at room temperature for 5 
minutes, with occasional vortexing, to facilitate lysis. Debris was pelleted by 
centrifugation and supernatant transferred to a fresh tube. Protein content of lysates 
was measured using a Bradford assay and equal amounts of protein from three 
biological replicates were combined to a total of 0.5 micrograms. Samples were heated 
to 100⁰C before separation on a 10% Bis-Tris gel. Membranes were blocked overnight 
in 2% milk in TBST. After overnight incubation, membranes were blotted with primary 
antibody against either GFP (1:1000 Santa Cruz, SC9996) or Actin (1:2000, Abcam, 
Ab3280). Stabilized peroxidase-conjugated goat anti-mouse antibody was used as 
secondary antibody (1:20,000, Jackson Immunologicals, 31430). Blots were developed 
using SuperSignal West Femto substrate (Thermo Scientific/Life Technologies).  
 
RNA isolation from mouse tissue. Mice were sacrificed at 10 weeks post-injection 
with an overdose of tribromoethanol (Avertin) (0.2 mL of 1.25% solution) and 
subsequent transcardial perfusion of PBS. Heart was removed and stored in RNAlater 
stabilization solution (Ambion/Life Technologies) until RNA harvest or DNA harvest (see 
below). To isolate RNA, tissue was disrupted in TRIzol (Invitrogen) using a TissueLyser 
(Qiagen). Once homogenized, samples were processed using the manufacturer’s 
protocol for TRIzol extraction of RNA from tissue.  
 
RNase R digestion. Five micrograms of RNA were DNase treated using the Turbo 
DNA-free kit (Ambion/Life Technologies). One microgram of DNase treated RNA was 
next preheated to 55⁰C for 5 minutes and treated with 1 unit of RNaseR (Epicentre) at 
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37⁰C for 10 minutes. Enzyme was inactivated at 95⁰C for 5 minutes. The resulting RNA 
was subject to RT-PCR as outlined below.  
 
RT-PCR.  Equal volume amounts of RNase R treated RNA was converted to cDNA 
using the High Capacity RNA-to-cDNA kit (Applied Biosystems/Life Technologies). 
Products of this reverse transcription reaction were utilized as template for PCR 
amplification using gene-specific primers for GFP (5’-CTG CTT GTC GGC CAT GAT 
ATA GAC GTT GTG GC-3’, 5’- CAA GCT GAC CCT GAA GTT CAT CTG CAC CAC C-
3’) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (5’-CCA CTC CTC CAC 
CTT TGA C-3’, 5’-ACC CTG TTG CTG TAG CC-3’). PCR products were visualized on 
an agarose gel. 
 
Vector genome quantification. DNA was extracted from 10-week timepoint tissue 
lysates using the DNeasy kit (Qiagen). Vector genome (vg) copies were quantified via 
qPCR using primers against the AAV ITR (5’-AAC ATG CTA CGC AGA GAG GGA 
GTG G-3’, 5’-CAT GAG ACA AGG AAC CCC TAG TGA TGG AG-3’). Vg values were 
normalized to copies of the mouse Lamin B2 locus (primers 5’-GGA CCC AAG GAC 
TAC CTC AAG GG-3’, 5’-AGG GCA CCT CCA TCT CGG AAA C-3’) for vg/cell values.  
 
4.4 Results and Discussion 
Design of an rAAV circRNA reporter. 
To visualize circRNA expression in mice, we cloned a split-GFP reporter into an 
rAAV vector backbone (circGFP) (Wang and Wang, 2015). In the circGFP reporter, 
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GFP is divided into two parts with the N terminal fragment placed downstream of the C 
terminal fragment (Figure 14A). The upstream fragment of GFP is preceded by a 
splicing acceptor sequence at its 5' end while the downstream fragment is followed by a 
splicing donor at its 3' end. The two GFP fragments are separated by an 
encephalomyocarditis virus (EMCV) IRES sequence. This ensures that, upon back-
splicing, full length GFP can be translated (Figure 14). Base pairing between flanking 
introns has been shown to facilitate circRNA formation (Ashwal-Fluss et al., 2014; 
Ivanov et al., 2015; Jeck et al., 2013; Kramer et al., 2015; Liang and Wilusz, 2014; 
Zhang et al., 2014). To take advantage of this property, split-GFP is flanked by 
IGF2BP1 introns which have been engineered to base pair (Wang and Wang, 2015) 
(Figure 14C). The entire cassette is driven by a CMV promoter and terminated with an 
SV40 p(A) signal (Figure 14A). Reconstituted, full length GFP RNA can be isolated from 
cells expressing the circGFP plasmid and, when sequenced, shows an intact splicing 
junction (Figure 14D). This indicates reliable and consistent backsplicing to form an in-
frame GFP open reading frame (ORF). 
We also generated two control rAAV vectors, the first of which expresses a full 
length GFP ORF (CMV-GFP) (Figure 15A). The second control vector, meant to 
account for IRES driven translation, consists of an EMCV IRES driving full length GFP 
(IRES-GFP) (Figure 15A). All constructs are expressed using the CMV promoter and 
SV40 poly-A signal.  
 
rAAV-mediated delivery of circGFP in mice. 
 rAAV packaging circGFP, CMV-GFP or IRES-GFP was administered via 
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intraperitoneal injection in postnatal day 2 (P2) BALB/c mouse pups. We chose to utilize 
mouse pups in order to observe the effects of rapid cell proliferation on expression of 
circRNA products. In more proliferative tissues, we expected dilution of both AAV 
episomes and circRNA over time. At 5.5, 10, and 16 weeks post-injection, GFP 
expression was detected by 3,3’-Diaminobenzidine (DAB) staining. Consistent with the 
robust transduction mediated by AAV9 throughout mouse tissue, GFP was discerned 
throughout the heart and liver from CMV-GFP at all timepoints (Pulicherla et al., 2011b) 
(Figures 15B, 15C). IRES-GFP treatment, however, resulted in minimal GFP detection 
(Figures 15B, 15C). Importantly, GFP was observed in the mouse heart out to 16 weeks 
post-injection and liver up to 10 weeks in circGFP treated tissue (Figures 15B, 15C). 
Full length GFP can only be expressed from circGFP upon RNA circularization. 
Therefore, GFP detection suggests that circRNAs were generated in these tissues.   
Detection of GFP from both CMV-GFP and circGFP was more robust in cardiac 
tissue relative to the liver, and in the case of circGFP, persisted to later timepoints 
(Figures 15B, 15C). This may be attributed to the highly proliferative nature of the liver. 
rAAV genomes, and presumably circRNA products, are subject to dilution as they are 
distributed throughout each cell division. The observed expression differences between 
heart and liver could also result from differential expression from the EMCV IRES in 
these tissues (Creancier et al., 2000).  
 
Molecular validation of circRNA production in mouse heart. 
We chose to focus our molecular analysis on 10-week post-injection cardiac 
tissue. Slides of DAB-stained heart sections from each timepoint were scanned to 
 77 
visualize global expression (Figure 16A). Expression of CMV-GFP was distributed 
evenly throughout the heart, while circGFP was detected at lower frequency (Figure 
16A). While equal doses of rAAV vector were administered in each mouse, it is possible 
that injection precision was not consistent. To detect potential variation in vector 
delivery, vector genomes (vg) were quantified via qPCR. The largest difference in 
genome copy in the heart was detected between circGFP and CMV-GFP treated tissue 
(Figure 16B). However, the two-fold difference between these two conditions is 
relatively low and statistically insignificant (p=0.294, two-tailed Student’s t-test). Vg 
copies detected from IRES-GFP treated cardiac tissue did not differ significantly from 
CMV-GFP or circGFP conditions (Figure 16B). Therefore, minimal detection of GFP 
from IRES-GFP vectors is likely not due to variation in vector delivery in the heart.  
 We performed RNase R digestion to confirm that circRNAs were, indeed, being 
produced in the heart of treated mice. While linear RNAs are susceptible to this 3' to 5' 
exonuclease, circRNAs are inherently resistant due to their lack of exposed ends 
(Suzuki et al., 2006). We isolated RNA from heart tissue of mice injected with rAAV 
CMV-GFP, IRES-GFP or circGFP and treated with RNase R. Products were converted 
to cDNA and amplified with either GAPDH or GFP specific primers. The RNase R 
negative conditions reflect relative expression of the RNA from each vector. Consistent 
with GFP staining, CMV-GFP produced the strongest GFP band while IRES-GFP and 
circGFP products were lower in intensity (Figure 16C). Importantly, the CMV-GFP and 
IRES-GFP products were both susceptible to RNase R while circGFP RNA remained 
RNase R resistant. This is consistent with circGFP forming a circular RNA (Figure 16C). 
As expected, linear GAPDH controls were susceptible to RNase R (Figure 16C).  
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Western blotting demonstrated that GFP is only detectable from CMV-GFP and 
circGFP tissues (Figure 16D). Further, though the CMV-GFP RNA is certainly more 
abundant relative to the circGFP RNA, GFP protein for both conditions is detected by 
western blot at similar levels (Figures 16C, 16D). This may suggest that the stability of 
circRNAs allows protein expression at comparable levels to that of linear mRNA, but 
with lower transcript abundance. Despite detection of the linear IRES-GFP RNA, GFP 
protein is not detectable from these tissues via western blot (Figures 16C, 16D). This 
highlights the importance of circularization for stable expression. Together, these 
observations support the hypothesis that the stability of circRNA constructs contributes 
to long term protein expression as compared to linear RNAs.  
 
Future prospects and implications for gene therapy. 
 Here we demonstrated the delivery and expression of translatable circRNA 
cassettes in mice using rAAV vectors. In the heart, circGFP expressed GFP at levels 
nearing that of a control full length GFP reporter (CMV-GFP) out to 16 weeks post-
injection (Figures 15C, 16D). Further, the GFP expression from circGFP was robust 
relative to that of a non-circularized control RNA (IRES-GFP) (Figures 15C, 16D). The 
difference between IRES-GFP and circGFP protein expression is likely a consequence 
of the stability of the circRNA over its linear IRES-GFP counterpart. These findings 
demonstrate the promise of circRNA-mediated protein expression in animal models. 
 While we demonstrate circRNA formation in vivo, the efficiency of circRNA 
biogenesis can likely be improved. One approach towards enhanced circularization 
could involve employing cis-acting sequences known to facilitate circRNA formation. For 
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example, Alu repeats have been identified in the introns flanking a number of exons 
known to circularize (Ashwal-Fluss et al., 2014; Ivanov et al., 2015; Jeck et al., 2013; 
Kramer et al., 2015; Liang and Wilusz, 2014; Zhang et al., 2014). The introns are 
thought to contribute to circRNA biogenesis by hybridizing through nucleotide-
complementarity, bringing the two splice sites into closer proximity. While our circGFP 
vector makes use of a similar strategy through engineered introns, the use of naturally 
occurring intron sequences may improve circularization efficiency. 
 Many rAAV-based therapeutics utilize short hairpin RNAs (shRNA) or microRNAs 
(miRNAs) to regulate gene expression, and have largely proved effective (Borel et al., 
2014). However, in some cases, overexpression of shRNAs yields hepatotoxicity or 
neurotoxicity (Borel et al., 2014; Grimm et al., 2006; van Gestel et al., 2014). This 
toxicity likely stems from saturation of the miRNA processing pathway and disruption of 
the normal cellular miRNA population (Grimm et al., 2006; Valdmanis et al., 2016; van 
Gestel et al., 2014). Similarly, it will be important to assess any potential toxicity 
resulting from circRNA vectors in mice. Investigating cellular splicing pattern variations 
upon circGFP overexpression could evaluate potential oversaturation of splicing 
machinery.  
While many clinical trials utilizing rAAV vectors for therapeutic applications have 
proved promising, dose-related toxicity still must be considered. Therefore, it would be 
beneficial to reduce the effective vector dose for rAAV vector-based therapeutics. 
CircRNAs are uniquely poised to address these issues. With a wide breadth of potential 
applications ranging from miRNA sponging to transcription regulation, circRNAs could 
prove useful in a myriad of situations. Combined with the well-defined tropisms of rAAV 
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vectors, rAAV-circRNA cassettes could allow tissue specific, stable expression of 
therapeutic agents. Further, though it remains to be directly tested, the stability of 
circRNAs could provide a mechanism for long term expression of therapeutic cassettes 
at a lower effective dosage. Ultimately, rAAV-delivered circRNA cassettes present a 
stable platform for in vivo gene expression.  
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Figure 14: Schematic of circGFP expression. (A) Schematic of the circGFP rAAV 
vector genome encoding a split-GFP cassette. (B) An mRNA encoding the split-GFP 
cassette is expressed from the circGFP rAAV genome. (C) Circularization is facilitated 
by hybridization of engineered IGF2BP1 introns to bring splice sites (grey triangles) into 
closer proximity. (D) Circularization reconstitutes the full length GFP ORF. A 
chromatogram depicting sequencing results of a GFP PCR product is depicted below 
the circRNA. Template cDNA was generated from RNA isolated out of circGFP 
transfected HEK293 cells. The splicing junction is indicated by a dashed red line. (E) 
GFP protein is expressed from the reconstituted GFP ORF encoded by the circRNA. 
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Figure 15: rAAV mediated delivery of circGFP expression cassette in mice. (A) Schematic representations of the 
rAAV vector genomes encoding each cassette used in this study. (B, C) 3,3’-Diaminobenzidine (DAB) stained heart (B) 
and liver (C) sections detecting GFP expression from mice expressing each rAAV-delivered cassette at 5.5, 10 and 16 
weeks post-injection. 
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Figure 16: Molecular characterization of circGFP expression products in mice. (A) 
3,3’-Diaminobenzidine (DAB) stained heart sections detecting GFP expression from 
mice expressing each rAAV-delivered cassette 10 weeks post-injection. Slide scans 
(top) of whole sections display widespread expression patterns while selected regions 
at higher magnification (bottom) reveal GFP expression by individual cells. (B) rAAV 
vector genomes per cell measured by qPCR in heart tissue for each rAAV cassette. 
Data are expressed as an average of three biological replicates. Statistical significance 
was calculated using a two-tailed Student’s t-test. No significance was detected. (C) 
PCR products detecting either GFP (left panel) or GAPDH (right panel) from cDNA. 
cDNA was generated from RNA isolated from mouse heart. RNA was treated with 
RNase R as indicated prior to reverse transcription. Mice were treated with rAAV 
delivering either CMV-GFP, IRES-GFP, or circGFP and RNA was isolated 10 weeks 
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post injection for analysis. (B) Western blot detecting GFP or Actin loading control. Cell 
lysates were used for loading were generated from mouse heart treated with rAAV 
packaging either CMV-GFP, IRES-GFP, or circGFP. Heart was harvested 10 weeks 
post-injection. 
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CHAPTER 5: SYNOPSIS AND FUTURE DIRECTIONS 
5.1 Summary 
The field of gene therapy has successfully driven the development of effective 
therapeutics for diseases including Leber’s congenital amaurosis and lipoprotein lipase 
deficiency. However, therapeutic gene expression requires careful regulation to protect 
against potential adverse effects. This dissertation focused on developing new 
approaches to regulate RNA stability for potential applications in gene therapy. To this 
end, I explored the use of the bacterial CRISPR endoribonuclease, Csy4, for 
manipulating RNA stability, and demonstrated the potential of rAAV-delivered circular 
RNA (circRNA) cassettes for protein expression in vivo. First, I established the 
functionality of Csy4 in human cells, as well as the ability of Csy4 to stabilize or 
destabilize an RNA based on target hairpin location. I found that Csy4 cleavage in the 3’ 
UTR of a poly(A)-deficient RNA can support the stabilization and translation of that 
RNA. Further, I developed an inducible circRNA cassette which switches from a linear 
isoform to a circular isoform upon Csy4 co-expression. I demonstrated that Csy4 
cleavage can remove competing downstream splicing signals to subsequently favor 
backsplicing of the RNA into a circRNA. Lastly, I delivered recombinant AAV (rAAV) 
encoding translatable circRNA cassettes in mice. I found that protein can be expressed 
from circRNA at a level nearing that of protein expressed from the linear isoform in vivo, 
despite the circRNA being present at lower relative abundance. Additionally, I found that 
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IRES-driven expression from these circRNA cassettes is more efficient in vivo 
compared to in cell culture.  
CircRNAs are particularly persistent and stable, offering an ideal potential 
platform for long-term gene expression. However, the circRNA expression cassettes 
presented here will require further engineering to develop optimal candidates for gene 
therapy applications. Additionally, due to the bacterial origin of Csy4, it will be important 
to characterize Csy4 further in a eukaryotic context. It may also be worthwhile to 
investigate the functionality of other Csy4 orthologs in human cells. In this chapter, I 
discuss approaches for characterizing and improving the novel technologies described 
in this dissertation. 
  
5.2 Further Evaluation and Regulation of Csy4 in Mammalian Cells 
Chapters 2 and 3 of this dissertation investigated the use of the CRISPR 
endoribonuclease, Csy4, in mammalian cells. While functional in human cells, Csy4 
originates from a bacterial system and certain aspects of Csy4 function in the eukaryotic 
environment remain to be determined.  
 For example, Csy4 recognizes the substrate hairpin through a number of 
sequence and structure specific interactions (Haurwitz et al., 2010; Sternberg et al., 
2012) (Figure 2). It is possible that Csy4 is capable of interacting with, and potentially 
cleaving RNA hairpins present in the human transcriptome. Studies identifying these 
RNAs could yield insight into the safety of Csy4 as a potential therapeutic. Further, if 
identified, understanding common sequence and structure characteristics of these 
endogenous Csy4-targeted RNAs would also be beneficial. This information could 
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additionally provide a starting point for application of Csy4 cleavage on endogenously 
expressed RNAs. In Chapter 2 of this dissertation, I demonstrated the interaction 
between Csy4 and the target hairpin by RNA immunoprecipitation (RNA-IP) (Figure 6). 
A similar strategy, sequencing purified RNA products of the RNA-IP, could reveal 
additional RNA binding partners.  
 It would also be worthwhile to investigate any potential interactions between 
Csy4 and cellular proteins. I observed translation of RNAs lacking poly(A) tails after 
Csy4 binding and cleavage of the RNA. The mechanism of translation after Csy4 
cleavage has not yet been elucidated, and could stem from a number of possibilities. 
For example, the remaining 3' phosphate and Csy4 binding after cleavage could 
stabilize the RNA long enough for translation to occur. Further, Csy4 could interact with 
translational initiation factors to recruit translation machinery. Hijacking of host 
translation machinery by exogenous protein factors is not unheard of. Indeed, influenza 
NS1 protein interacts with the eukaryotic translation initiation factor eIF4GI and poly-A 
binding protein (PABP) (Aragon et al., 2000; Burgui et al., 2003). This interaction 
recruits translational machinery to the viral RNA for efficient translation (Aragon et al., 
2000; Burgui et al., 2003). Therefore, elucidating Csy4 interactions with cellular proteins 
may provide insight into the mechanism behind translation of Csy4 cleaved mRNAs.  
 It may also be useful to develop methods for regulating Csy4 activity to exercise 
tight control over Csy4-mediated effects. Small molecule screens may reveal drugs 
capable of inhibiting Csy4 catalytic activity. Further, taking advantage of Csy4’s tight 
interaction with the target hairpin, expression of a decoy hairpin may dilute the effective 
Csy4 population. 
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5.3 Future Applications and Engineering of Csy4 
Csy4 as a “safety switch” 
In this dissertation, I demonstrated new applications of Csy4 for regulating 
transgene expression and circRNA formation. These findings may serve as a starting 
point for the development of new technologies and applications of Csy4. For example, 
Csy4 could act as an effective “safety” switch, for turning off gene expression. Safety 
switches are becoming increasingly valuable in gene and cell therapy as precautions for 
unintended reactions to treatment (Jones et al., 2014). The use of cell-killing genes (ie: 
Caspase-9 and herpes simplex virus thymidine kinase (HSV-TK)) as safety switches 
has been described previously (Bonini et al., 1997; Di Stasi et al., 2011). In one 
rendition of a Csy4-based safety switch, the circGFP-CD cassette could be modified for 
expression of a cell-killing gene in the presence of Csy4. The cell-killing gene would be 
arranged in a split orientation and replace the split-GFP cassette such that it only 
expresses in a circular configuration. Meanwhile, the dsRed sequence would be 
replaced with a therapeutic gene. Thus, in the absence of Csy4, the therapeutic protein 
would be expressed from a linear RNA. Should the therapy prove detrimental, Csy4 
could be delivered for switching off the therapeutic protein and inducing circRNA 
formation. Subsequent expression of the cell-killing protein would cause cell death to 
prevent further expression of the detrimental therapeutic.  
 
Csy4 orthologs and recognition of new targets 
           Exploring the function of Csy4 orthologs from other Class 1 Type I CRISPR 
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systems in a mammalian context may also prove beneficial (Brouns et al., 2008; Carte 
et al., 2008; Hochstrasser and Doudna, 2014; Nam et al., 2012). If catalytic activity is 
retained in a mammalian context, it would be interesting to explore whether these 
orthologs are capable of gene regulation in a manner similar to Csy4. Like Csy4, many 
Class I Type I, pre-crRNA processing enzymes remain associated with the cleaved 
crRNA product (Carte et al., 2010; Nam et al., 2012; Sashital et al., 2011). However, the 
binding affinities of each enzyme for the cleavage product vary and most generate a 
2',3'-cyclic phosphate terminal end (Jore et al., 2011; Nam et al., 2012). This differs 
from the tight association (Kd ≈ 50 pM) between Csy4 and the 3’-phosphate-containing 
cleavage product (Sternberg et al., 2012; Wiedenheft et al., 2011). Therefore, it would 
be worthwhile to investigate whether these orthologs also stabilize 3’ ends and support 
mRNA translation.  
It may also be possible to engineer Csy4 for binding and cleaving new 
substrates. Substrate recognition is carried out through a series of sequence- and 
structure-specific contacts between Csy4 and the target RNA hairpin (Haurwitz et al., 
2010; Sternberg et al., 2012). Structure-specific contacts are mediated by an Arginine 
rich helix which docks into the major groove of the target RNA hairpin (Haurwitz et al., 
2010; Sternberg et al., 2012) (Figure 2). Meanwhile, Arg102, Gln104, and Arg115 are 
responsible for sequence-specific recognition of G20, A19 and G11 of the hairpin 
respectively (Sternberg et al., 2012) (Figure 2). Lastly, Phe155 orients G20 in the active 
site through base-stacking interactions (Haurwitz et al., 2010; Sternberg et al., 2012) 
(Figure 2). Approaches for engineering Csy4 for new substrate binding might include 
randomization of codons encoding residues involved in hairpin recognition. A proof-of-
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concept strategy could involve restricting randomization to the residues recognizing 
specific nucleotides of the target hairpin (Arg102, Gln104, Arg115). This approach 
would potentially yield Csy4 variants capable of binding hairpins with differing 
nucleotides at positions 11, 19, and 20 of the hairpin. However, perhaps future efforts 
could be directed at engineering Csy4 to bind RNA structures differing from the 
canonical short hairpin.  
 
5.4 Improving Current CircRNA Expression Cassettes 
In Chapter 4 of this dissertation, I demonstrated that rAAV vectors can be utilized 
for delivering circRNA expression cassettes in mice. The circRNAs produced from these 
cassettes can be translated in vivo and persist until at least 16 weeks post-injection. 
While these vectors are a promising start towards circRNA based therapeutics, the 
efficiency of circRNA biogenesis and translation of circRNAs can likely be improved. To 
this end, I propose two strategies for optimizing AAV circRNA vectors.  
First, translation efficiency can be optimized through the incorporation of various 
Internal Ribosome Entry Site (IRES) elements. The current vectors utilized in Chapter 4 
rely on the widely expressed encephalomyocarditis virus (EMCV) IRES for protein 
translation. However, exchanging this IRES for others with alternate translation 
specificities and efficiencies may help fine tune expression for therapeutics of interest. 
For example, the Fibroblast Growth Factor-2 (FGF-2) IRES exhibits tissue specific 
translation activity with highest expression in mouse testis and brain (Creancier et al., 
2000). Thus, exchanging the EMCV IRES for the FGF-2 IRES in circRNA-based protein 
expression systems may add a layer of tissue specificity. 
 91 
A second strategy for improving AAV circRNA vectors is through enhancing 
circRNA biogenesis. CircRNA formation requires canonical splicing machinery and 
splicing signals such as the polypyrimidine tract and branch point (Starke et al., 2015). 
However, additional factors have been implicated in circRNA biogenesis. For example, 
Alu repeats have been identified flanking exons known to circularize (Ashwal-Fluss et 
al., 2014; Ivanov et al., 2015; Jeck et al., 2013; Kramer et al., 2015; Liang and Wilusz, 
2014; Zhang et al., 2014). It is hypothesized that these repeat sequences base pair to 
bring splicing signals into close proximity for backsplicing. Indeed, mutations disrupting 
base pairing between these flanking sequences reduces the efficiency of circRNA 
formation (Kramer et al., 2015; Liang and Wilusz, 2014). The current circGFP cassette 
utilizes a set of engineered IGF2BP1 introns which were designed to base pair to 
promote circRNA biogenesis. However, the use of naturally occurring, Alu repeat 
containing introns may provide a more effective option for promoting circularization. 
Furthermore, as circRNAs often display tissue specific expression patterns, these 
introns could potentially contribute to tissue specificity of circRNA biogenesis (Liang and 
Wilusz, 2014; Salzman et al., 2013; Zheng et al., 2016).  
 I sought to explore the benefit of Alu repeat-containing introns on circRNA 
biogenesis in vivo. Towards this end, I cloned portions of introns flanking ZKSCAN1 
exons two and three and those flanking HIPK3 exon two into GFP reporter rAAV 
plasmid backbones (Liang and Wilusz, 2014) (Figure 17A). I expect that, for therapeutic 
applications, maximal protein expression would be attained from translating protein from 
both linear and circular RNAs. Therefore, initial characterization of these vectors was 
carried out using an un-split GFP reporter exon. However, it will be important to also 
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investigate reporter expression of these cassettes using split-GFP cassettes in the 
future. I also utilized the control IRES-GFP cassette, which lacks flanking intron 
sequences and corresponding splicing signals (IRES-GFP) (Figure 17A).  
 Reporter cassettes were packaged into rAAV and characterized by infecting 
HEK293 cells at 50,000 MOI (multiplicity of infection). GFP expression for each vector 
was observed at 48 hours post-transfection by fluorescence microscopy (Figure 17B). 
However, I cannot definitively conclude that GFP signal is a result of expression from 
circRNA over linear mRNA. To demonstrate the presence of circRNAs, I isolated total 
cellular RNA and treated with RNase R. Linear RNAs are susceptible to this 3' to 5' 
endoribonuclease while circRNAs are resistant due to their lack of exposed ends 
(Suzuki et al., 2006). GFP RNA was detected from each condition at similar levels in the 
absence of RNase R (Figure 17C). As expected for a linear RNA, IRES-GFP RNA was 
depleted upon treatment with RNase R. Conversely, ZKSCAN1-GFP and HIPK3-GFP 
RNA demonstrated resistance to RNase R, consistent with circRNA formation (Figure 
17C). Together, these data suggest that the ZKSCAN1-GFP and HIPK3-GFP rAAV are 
capable of producing circRNA and can express GFP protein. 
 I next delivered each rAAV vector into mice, in order to understand any tissue or 
cell-type specific differences in expression conferred by each set of introns. I utilized 
AAV serotype 9, which demonstrates widespread expression throughout mouse tissues 
(Pulicherla et al., 2011b). Adult BALB/c mice were injected intravenously with rAAV 
packaging either IRES-GFP, ZKSCAN1-GFP, or HIPK3-GFP (five mice per cassette). 
Six weeks post-injection, heart and liver were harvested from each mouse and GFP 
was detected using 3,3'-Diaminobenzidine (DAB) staining. In the heart, ZKSCAN1-GFP 
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displayed the most abundant GFP levels relative to the other tested cassettes (Figure 
18A). HIPK3-GFP also expressed GFP in the heart, though, not to the levels observed 
with ZKSCAN1 introns (Figure 18A). The IRES-GFP control displayed minimal GFP 
expression, highlighting the importance of circularization for GFP expression (Figure 
18A). In contrast, expression from all vectors in the liver was consistently low (Figure 
18B). This pattern may be a consequence of rAAV vector genome dilution resulting from 
liver proliferation. However, further studies will need to be completed to fully understand 
this observation.  
 CircRNAs are particularly abundant in the mammalian brain (Rybak-Wolf et al., 
2015; You et al., 2015). Therefore, I tested expression of our reporter cassettes in the 
mouse brain. rAAV vectors expressing each reporter construct were separately 
administered into P1 (postnatal day 1) pups via intracerebroventricular (ICV) injection. 
Brains were harvested six weeks post-injection, sectioned, and GFP expression was 
detected using DAB staining. Each cassette displayed unique expression patterns 
characterized by both regional and cell type expression. GFP positive cells for control 
IRES-GFP were detected occasionally in the cortex and the lining of the lateral ventricle 
(Figure 18C). Cortical expression was primarily neuronal with occasional astrocytic 
staining. In contrast, ZKSCAN1-GFP mediated GFP expression was more widespread. 
GFP positive cells were detected in the olfactory bulb, cortex, and occasionally in the 
hippocampus and cerebellum (Figure 17C). Cortical and hippocampus expression was 
primarily astrocytic while expression in the olfactory bulb and cerebellum was largely 
neuronal. HIPK3-GFP, in contrast, was expressed mainly in cortical astrocytes, with 
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occasional neuronal staining in the olfactory bulb, and expression in the lining of the 
ventricle (Figure 18C). 
As the only difference between these cassettes is the flanking introns, these 
expression patterns are likely a conferred by the introns. Indeed, expression for certain 
circRNAs in the brain is region specific, which may imply regulation by regional and/or 
cell-type specific factors (Rybak-Wolf et al., 2015; Veno et al., 2015). 
 
5.5 CircRNAs Containing an EMCV IRES are Efficiently Translated in Mice 
There was a striking difference between protein expression from the same 
circRNA expression vectors in cell culture versus in mouse tissues. For example, when 
IRES-GFP, ZKSCAN1-GFP and HIPK3-GFP were delivered into HEK293 cells via 
rAAV, GFP fluorescence was similar between cells expressing each construct (Figure 
17B). However, in mouse tissue (both in the heart and the brain) GFP production from 
each cassette was starkly different compared to HEK293 cells (Figure 18). IRES-GFP 
generated minimal GFP signal while the ZKSCAN1 and HIPK3 intron flanked cassettes 
produced strong GFP signal (Figure 18). This difference in expression pattern between 
cultured cells and mouse tissue reflects improved EMCV IRES translation efficiency in 
the background of mouse cardiac and brain tissue compared to HEK293 cells. 
Furthermore, these differences also suggest that the context of a linear RNA vs a 
circular RNA also plays a role in translation efficiency from the IRES. Therefore, it would 
be worthwhile to conduct additional studies to evaluate the contribution of the IRES on 
protein expression from these cassettes in vivo and in vitro, and in a linear versus 
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circular RNA context. These studies would allow for more informed design of 
therapeutic cassettes.  
 
5.6 Future Evaluation of rAAV CircRNA Expression Cassettes 
 Further studies will need to be completed to confirm the presence of circRNAs in 
the tissues tested here. RNase R digestion of RNA harvested from mice expressing 
each rAAV vector would determine the ratio of circular to linear RNA present in each 
tissue. Further, use of split-GFP cassettes (as used in Chapter 4) flanked by each intron 
pair would more accurately reflect circRNA-specific translation products. Here, 
identification of neurons and astrocytes was determined by visual inspection of cell 
morphology. Immunostaining for cell-type specific markers would confirm cell identity. In 
addition, it would be informative to quantify vector genomes from each tissue to validate 
that each mouse received a similar dose of AAV. This would rule out expression 
differences attributed to lower effective vector delivery. Last, evaluation of toxicity and 
changes in overall cellular splicing patterns will be important for establishing the safety 
of circRNA platforms for gene expression.  
 
5.7 Final Remarks 
This dissertation described the development of new approaches to regulate RNA 
stability. I demonstrated that the bacterial CRISPR endoribonuclease Csy4/Cas6f is not 
only functional in human cells, but can also be applied to regulate RNA stability and 
circRNA biogenesis. In addition, I demonstrated delivery of translatable circRNA 
expression cassettes in vivo using rAAV vectors. The results described here add novel 
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tools to the array of CRISPR-derived technologies and raise new questions regarding 
translation of Csy4-bound RNAs. Further, these findings also provide a starting point for 
developing RNA-based therapeutic safety-switches. Finally, these studies lay the 
groundwork for expressing therapeutic circRNA cassettes via rAAV vectors. 
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Figure 17: In vitro expression of circRNA reporters from viral vectors. (A) Schematic representations of rAAV 
genomes encoding reporter cassettes IRES-GFP, ZKSCAN1-GFP and HIPK3-GFP. The length of each intron segment is 
indicated below the respective intron. Splice sites are represented by grey triangles. (B) GFP expression detected by 
fluorescence microscopy from HEK293 cells. HEK293 cells were infected at 50,000 Multiplicity of Infection (MOI) with 
rAAV vectors expressing either IRES-GFP, ZKSCAN1-GFP, or HIPK3-GFP. (C) PCR products from cDNA template 
generated after RNase R treatment of RNA. Primers were designed to detect the GFP coding sequence. RNA was 
isolated from HEK293 cells infected with IRES-GFP, ZKSCAN1-GFP, or HIPK3-GFP at 50,000 MOI. 
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Figure 18: in vivo expression of circRNA reporters from viral vectors. (A, B) 3,3'-
Diaminobenzidine (DAB) stained heart (A) and liver (B) sections detecting GFP 
expression from rAAV-delivered IRES-GFP, ZKSCAN1-GFP or HIPK3-GFP cassettes. 
Slide scans (top) of whole sections display global expression patterns while selected 
regions at higher magnification (bottom) reveal expression of individual cells. (C) DAB 
stained sagittal brain sections detecting GFP expression from rAAV-delivered IRES-
GFP, ZKSCAN1-GFP or HIPK3-GFP cassettes. Various brain regions are indicated by 
the following abbreviations. OB: Olfactory bulb; CT: cortex; LV: lateral ventricle; HC: 
hippocampus; CB: cerebellum. Examples of astrocytic cells and neuronal cells are 
indicated by a filled triangle or arrowhead respectively.   
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